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INTRODUCTION 
What makes the BP in pregnancy to rise; 
Is still a mystery to many a wise - 
How can we find a method of cure? 
When the causative factor still remains obscure! 
Pre-eclampsia and eclampsia remain one of the serious 
complications of pregnancy occurring in approximately 7-10 % of 
pregnant women1.  
According to WHO, it constitutes for about 5 % pregnancies and is 
responsible for 17.2% of maternal mortality rate and 22% of perinatal 
mortality rate in India 2. 
The principles of management of this condition include control of 
blood pressure using antihypertensives, control of convulsion, monitoring 
complications and steps for delivery of fetus3. 
The optimal anticonvulsant for management of severe 
preeclampsia and eclampsia was disputed till the Eclampsia Collaborative  
Group published its results in 1995, showing clearly that magnesium 
sulphate is more efficacious than phenytoin or diazepam in diminishing 
the risk of further convulsions and also in decreasing maternal and 
neonatal mortality4.  
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The publication of MAGPIE trial in 2002, finally resolved the long 
standing controversy and uncertainity on whether prophylaxis is useful in 
preventing the first seizure in severe preeclampsia and that magnesium 
sulphate was the agent of choice5.       
However in many PHC’s and peripheral hospitals magnesium 
sulphate has still not gained popularity because of fear of the rare but 
sometimes fatal toxicity of respiratory depression. This led to the search 
for an optimum dosage regimen for women smaller than their western 
counterpart. 
            In 1998, study concluded in Dhaka, developed a low dose (Dhaka) 
regimen, which appeared to control and prevent convulsions effectively 
and had a low side effect profile than the Pritchard regimen 6. 
To determine whether the low dose regimen has less side effects 
while at the same time being equally effective as the Pritchard regimen, a 
randomized clinical trial was carried out. 
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REVIEW OF LITERATURE 
Hypertensive disorders complicating pregnancy are common and 
form one of the deadly triad, along with haemorrhage and infection, that 
contribute greatly to maternal morbidity and mortality 7 
Preeclampsia and eclampsia remain a difficult puzzle to solve. It is 
complex hypertensive disorder of pregnancy affecting multiple systems. 
Preeclampsia and eclampsia are not distinct disorders but are 
differentiated according to their clinical symptoms. The mildest disorder 
in this continuum is gestational hypertension. In preeclampsia 
hypertension and proteinuria are present, and when convulsions occur in 
addition to these signs, the condition is referred as eclampsia. 
Traditionally it was believed that eclampsia evolves in a fairly linear 
fashion from mild to severe form of preeclampsia to seizures. It is now 
known that the progression from mild preeclampsia and eclampsia may 
not occur in all women. In a retrospective study Katz et al 8, found that in 
60% of cases seizures were the first sign of preeclampsia. However in 
severe preeclampsia compared to mild preeclampsia, the incidence of 
eclampsia increases three fold (3% and 1% respectively) 9 
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DEFINITION AND CLASSIFICATION OF PREECLAMPSIA 
DEFINITION - ACOG 
              Pre-Eclampsia is defined as a rise in diastolic BP of 90 mm Hg 
or more or systolic BP of 140 mm Hg or more recorded on at least two 
occasions  six   hours   apart  and  the  development of  Proteinuria of  
300 mg/L or more in 24 hours or presence of 1 gm or more per litre at 
random on at least two occasions six hours apart after 20 weeks of 
gestation in a previously normotensive nonproteineuric woman and which 
regresses postpartum. 
CLASSIFICATION  
1. NATIONAL HIGH BLOOD PRESSURE EDUCATION 
PROGRAM WORKING GROUP     (2000) 
Gestational hypertension 
 BP>140/90 mmHg for first time during pregnancy 
 No Proteinuria 
 BP returns to normal <12 wks postpartum 
 Final diagnosis made only postpartum 
 May have other signs / symptoms of preeclampsia for example, 
epigastric discomfort or thrombocytopenia 
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Preeclampsia 
Minimal criteria 
  BP >140/90 mmHg after 20 weeks gestation 
 Proteinuria   >300 mg/24 hrs or >1+ dipstick 
Increased certainty of preeclampsia 
 BP>160/110 mmHg 
 Proteinuria 2.0g/24 hr or >2+ dipstick 
 Serum creatinine >1.2 mg, unless known to be previously elevated 
 Platelets  < 1,00,000/mm3 
 Microangiopathic hemolysis  
 Elevated SGOT/SGPT/LDH 
 Persistent headache or other cerebral or visual disturbances 
 Persistent epigastric pain 
Eclampsia   
Seizures that cannot be attributed to other causes in a women with 
preeclampsia 
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Superimposed preeclampsia on chronic hypertension 
 New onset proteinuria 300 mg/24 hr in hypertensive women but no 
proteinuria before 20 weeks gestation 
 A sudden increase in proteinuria or BP or platelet count 
<1,00,000/mm3 in women with hypertension and proteinuria before 
20 weeks gestation. 
Chronic hypertension 
 BP >140/90 mmHg before pregnancy or diagnosed before  
20 weeks gestation not attributable to gestational trophoblastic 
disease (or) 
 Hypertension first diagnosed after 20 weeks gestation and 
persistent after 12 weeks postpartum 
PROTEINURIA 
Proteinuria is an important sign of preeclampsia. It reflects the 
degree of glomerular damage that causes leakage of proteins through the 
basement membrane. The amount of proteinuria is used as an indicator 
for assessing the severity of preeclampsia. Significant proteinuria is 
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described as 300mg per litre or more of urinary protein loss in 24 hours or 
persistent 30mg/dl (1+ dipstick) in random clean catch samples on at least 
2 occasions collected 6 hours apart. If proteinuria is > 5gm /24 hours or 
persistent 2+ dipstick or more the condition is labelled as severe  
pre-eclampsia. 
Dipsticks are routinely used to measure proteinuria and the colour 
changes correspond to  
          Protein; Trace – 0.1 gm/L 
1+  – 0.3 gm/L 
2+ – 1.0 gm/ L 
                               3+   – 3.0 gm/L 
                               4+    – 10.0 gm /L 
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INDICATORS FOR SEVERITY OF PREECLAMPSIA 
ABNORMALITY MILD SEVERE 
Diastolic BP <100 mm Hg 110mmHg or higher 
Proteinuria Trace to  1 Persistent 2 +or more 
(at least  5 gm /24 hrs ) 
Headache Absent Present 
Upper abdominal pain Absent Present 
Oliguria Absent Present(output less than 
400 -500 ml ) 
Convulsion Absent Present (Eclampsia) 
Serum creatinine Normal Elevated 
Thrombocytopenia Absent present 
Elevated liver enzymes Minimal Marked 
Fetal growth restriction Absent Obvious 
Pulmonary edema Absent Present 
 
 One or more of the above criteria must be present for the condition 
to be labelled as severe preeclampsia. 
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INCIDENCE OF PREECLAMPSIA 
          The incidence of preeclampsia is 7-10% depending on the 
population studied and definition of preeclampsia. The incidence of 
preeclampsia and eclampsia in Institute of Obstetrics and Gynaecology, 
Chennai is 12–14%.Worldwide approximately 50,000 women are 
estimated to die annually because of eclampsia. The overall maternal 
death rate of eclampsia is 2%, but varies geographically according to the 
quality of area’s health care system. Death related to toxemia of 
pregnancy accounts for 11% of maternal deaths in India10. Preeclampsia 
and eclampsia are also among the major contributors to perinatal 
mortality and morbidity. The perinatal mortality among babies born to 
eclamptic mothers was 32.7% compared to 10.5 % for total perinatal 
mortality11. Preeclampsia is strongly associated with IUGR, low birth 
weight, preterm delivery, respiratory distress syndrome and admission to 
NICU. 
How pregnancy incites or aggravates hypertension remain 
unknown.Intensive research is ongoing,regarding the risk factors that may 
predispose and the predictors of this condition and whether prevention is 
possible by any pharmacological or non pharmacological strategies. 
RISK FACTORS FOR PREECLAMPSIA               
Certain women have been identified to be at risk for development of 
hypertensive disorders of pregnancy12. 
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RELATIVE RISK FACTORS   
GENETIC FACTORS 
Genetic predisposition  
Ethnicity: more common in Blacks &Asians 
Family H/O preeclampsia                
Pregnancy by ovum donation  
AGE & PARITY 
 Teenage pregnancy 
         Age > 40 years  
 Long interval between pregnancies  
         Nulliparity  
PARTNER RELATED RISK FACTOR 
        Change of partner 
         Limited sperm exposure 
         Donor insemination 
         Partner who fathered a preeclamptic pregnancy in another woman 
         Presence of specific underlying disorders 
         Chronic hypertension  
         Renal disease  
         Obesity (body mass index > 35 kg/m2) 
         Diabetes mellitus       
         Maternal low birth weight 
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         Polycystic ovarian syndrome 
         Migraine 
         Collagen vascular disorders 
         Uncontrolled hyperthyroidism 
         Factor V leiden deficiency & thrombophilia                                                              
         Activated protein C resistence, protein S deficiency 
         Antiphospholipid antibodies  
         Hyperhomocysteinemia 
         Sickle cell disease, sickle cell trait 
         Women with excessive snoring 
Pregnancy related risk factors  
         Multiple pregnancy  
         Congenital anomalies 
         Hydrops fetalis 
         Chromosomal anomalies (trisomy 13, triploidy) 
         Hydatiform mole 
         Urinary tract infection    
Exogenous factors 
         Smoking (risk reduction) 
         Stress, work related psychological stress 
         Previous H/O preeclampsia  
         Raised BP (diastolic >80) at booking  
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ETIOPATHOGENESIS 
The pathophysiology of disease is far from being understood. 
Ziefel described it as ‘disease of theories’. Any satisfactory theory 
concerning the etiology of pathophysiology of preeclampsia must account 
for the observation that hypertensive disorders due to pregnancy are very 
much likely to develop in women  
i) who are exposed to chorionic villi for first time 
ii) who are exposed to superabundance of chorionic villi as with 
twins and hydatiform mole  
iii) have preexisting vascular disease 
iv) Are genetically predisposed to hypertension developing 
during pregnancy 
Roberts et al., proposed that maternal endothelial cell dysfunction 
is the key event resulting in diverse clinical manifestations of 
preeclampsia and considered preeclampsia as a two stage disease 13 . The 
initiation of preeclampsia seems to be related to decreased placental 
perfusion (stage 1) which then results in the maternal syndrome of 
preeclampsia (stage 2). The maternal syndrome reflects a state of 
generalized dysfunction secondary to excessive amount of circulating 
antiendothelial factors such as SFlt – 114.                         
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Although chorionic villi are essential, they need not be located 
within the uterus. A fetus is not a requisite for preeclampsia . Regardless 
of precipitating etiology, the cascade of events that lead to preeclampsia 
is characterized by a host of abnormalities that result in vascular 
endothelial damage with vasospasm, transudation of plasma and ischemic 
and thrombotic squeal. (Brunner and Gavras, 1975). 
According to Sibai (2003), currently plausible potential causes 
include the following 
i) Abnormal trophoblastic invasion   
 Failure of secondary wave of trophoblastic invasion, which 
mainly occurs at 16-20 wks. This trophoblastic invasion of 
spiral arterioles is responsible for destruction of muscular 
layer making vessels lose their refractoriness to 
vasopressors15. 
ii) Immunological intolerance between maternal and fetoplacental 
tissues 
 Risk of hypertensive disorders is enhanced in circumstances 
where formation of blocking antibodies to antigen sites in 
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placenta may be impaired as in first pregnancy and multiple 
pregnancy16,17 
iii) Maternal maladaption to cardiovascular or inflammatory 
changes of normal pregnancy18 
iv) Dietary deficiencies - deficiency of Zinc, Calcium, Mg, Vit C19 
v) Genetic predisposition  
           Chesley & Cooper (1986)20 concluded that preeclampsia is 
highly heritable. Wilson & coworkers (2004) reported 60% 
concordance in monozygotic female twin pairs. An 
association with HLA DR4 & Angiotensinogen gene T235 
was found to have higher incidence of preeclampsia21. 
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MULTISYSTEM   EFFECTS OF PREECLAMPSIA 
Brain - edema, haemorrhage, infarction 
Eyes - sudden retinal detachment, cortical blindness, 
papilledema 
CVS - Hypertension, pulmonary edema 
RS - Pulmonary edema, aspiration pneumonitis 
Liver - congestion, hemorrhage, infarction, rupture 
Kidney - glomeruloendotheliosis, nephrotic syndrome, ARF 
Blood - thrombocytopenia, microangiopathic hemolytic 
anemia, DIC 
Reproductive - IUGR, prematurity, placental abruption, IUD 
Skin - edema, petechia, ecchymosis 
Mucosa - laryngeal edema   
PREDICTION OF HYPERTENSIVE DISORDERS OF 
PREGNANCY 
A variety of biochemical and biophysical markers primarily on 
rationales implicated in the pathology and pathophysiology of 
preeclampsia have been proposed for its prediction, but to utmost 
disappointment of  many  workers there is no reliable, valid or 
economical screening test available for the prediction of preeclampsia 
(Friedman and Lindheimer) 22.     
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Mid trimester Blood Pressure  
The absence of fall in mid trimester blood pressure has been noted 
in many patients who later on developed preeclampsia. Women with a 
mid trimester mean arterial pressure >90mm Hg have a three fold risk of 
developing preeclampsia. 
Roll over test 
           An increase of > 20mm Hg of diastolic BP induced by having 
women at 28-32 weeks assume the supine position after lying laterally 
recumbent predicted gestational hypertension with a positive predictive 
value of 33% (Gant and Colleagues)23. 
Handgrip test 
Degari et al., found that increase in diastolic BP >20mmHg during 
a hand grip test at 28-32 weeks is associated with increased incidence of 
preeclampsia with a sensitivity of 81% and specificity of 68.4%.   
Angiotensin II infusion test  
Women requiring less than 8ng/kg/min of angiotension II to raise 
their diastolic BP by 20 mm Hg had a positive predictive value of  
20-40% of developing preeclampsia (Freidman).  
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Uric acid 
          Elevated serum uric acid level due to deceased urate excretion are 
frequently found in women with preeclampsia. Plasma uric acid value 
exceeding 5.9 mg/dl at 24 wks has a positive predictive value of 33%. 
(Jacobson and Colleagues). 
Urinary calcium excretion 
24 hours urinary calcium excretion less than 12mg/dl  
had a sensitivity of 70% and a positive predictive value of 91%  
(Sanchez – Romos). 
Urinary Kallikrein excretion 
Kallikrein is an important regulator of blood pressure and it has 
been observed that its diminished excretion due to reduced levels in the 
circulation might precede development of preeclampsia (Miller et al). 
Urinary kallikrein creatinine ratio at 16 – 20 weeks can be used to predict 
patients at risk for preeclampsia. 
Serum fibronectin 
Endothelial cell activation is the likely cause of elevated serum 
cellular fibronectin levels in some women with preeclampsia. In patients 
with preeclampsia, a 2 fold increase in fibronectin >400ng/ml is seen.  
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It has a sensitivity of 69% and positive predictive value of 12 %. 
(Pallberg and Colleagues) 24. 
Uterine artery Doppler velocimetry  
Measurement of uteroplacental vascular resistance during Doppler 
ultrasound evaluation of uterine artery impedance in the second trimester 
has been used as early screening test for preeclampsia (Bweley)25. 
Audibert and coworkers (2005)26 combined second trimester maternal 
serum screening for βHCG and AFP with uterine artery notching and 
found sensitivity that ranged from 2 – 40%. 
PREVENTION OF PREECLAMPSIA - IS IT POSSIBLE? 
The therapeutic options available to the patient and her physician 
once a diagnosis of preeclampsia has been made are very limited. For this 
reason, much attention has been focussed on strategies for primary 
prevention and on the identification of subgroups of women with 
preeclampsia who would benefit from such intervention. 
NON PHARMACOLOGICAL PREVENTIVE STRATEGIES 
1)  Bed  rest  
Has not been conclusively shown   to prevent the development or 
alter the course of proteinuric   hypertension27 .   
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2) Dietary sodium restriction   
There is no convincing evidence that salt restriction has any role to 
play in either the prevention or treatment of hypertensive disorders of 
pregnancy. The physiological volume expansion of uncomplicated 
pregnancy and the association of chronic hypertension, preeclampsia and 
intrauterine growth restriction with plasma volumes lower than those 
measured in normal pregnancy are the common reasons cited for why 
sodium restriction generally is not recommended to treat hypertension 
during pregnancy28.  
3) Dietary supplementation   
A study by the Dietary Approaches to Stop Hypertension (DASH) 
Collaborative Group demonstrated that dietary manipulation could 
significantly lower both systolic and diastolic blood pressure29. 
Zinc and magnesium supplements were tried, though there is no 
evidence to prove that they prevent preeclampsia 30.    
Few non randomized studies showed that supplementation of 
vitamin C & vitamin E as antioxidant therapy helps in prevention of 
preeclampsia but confirmation by large scale studies are still needed31.     
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Calcium supplementation – initial clinical trials suggested that 
dietary calcium support during pregnancy is associated with substantial 
benefit in decreasing the incidence of preeclampsia. Recent studies show 
no benefit. A recent randomized double masked NICHD trial showed that 
there was no benefit in calcium supplementation32. 
Fish oil capsules were supplemented, but that again proved 
ineffective 33. 
L- Arginine has been found to be useful in the prevention of 
preeclampsia, but it was an isolated study and no other studies confirmed 
its findings34. 
PHARMACOLOGICAL PREVENTIVE STRATEGIES    
Diuretics 
A review of nine randomized placebo controlled studies involving 
7700 women, where diuretics were given to prevent preeclampsia showed 
no difference in incidence of preeclampsia or perinatal mortality 35.  
Antihypertensives 
There is no evidence that antihypertensive agents can prevent 
preeclampsia, although the use of antihypertensive agents in women with 
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preeclampsia and severe elevation in BP (170/110mmHg) has been 
shown to prevent cerebrovascular accidents, such treatment does not alter 
the natural course of the disease36. 
Low dose aspirin 
Aspirin blocks production of eicosonoids, by irreversibly inhibiting 
the action of enzyme cyclooxygenase (COX) which is the rate limiting 
step in the prostanoid biosynthetic cascade. Thromboxane from platelets 
produces vasoconstriction and platelet aggregation whereas prostacyclin 
produced by vascular endothelial cells is vasodilator and inhibits platelet 
aggregation. An imbalance in favour of vasoconstriction and platelet 
aggregation (TXA2 > PGI2) has been demonstrated early in pregnancies 
destined to develop preeclampsia and has been implicated in the 
pathophysiology. 
          The platelets lack DNA genome and therefore unable to regenerate 
COX enzyme, theoretically therefore aspirin should alter the process by 
tipping the balance in favour of production of PGI2. 
Early clinical trials and meta analysis suggested that low dose 
aspirin can be used with no associated risk to mother and fetus37. These 
reports led to the widespread use of prophylactic aspirin to prevent 
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preeclampsia. The largest trial to date CLASP study, a multicentre trial 
incorporating large number of patients, however, suggest that low dose 
aspirin has very little, if any, effect on the incidence of preeclampsia and 
may indeed have significant adverse effects (most notably a possible 
increased risk of abruptio placenta) 38. 
Thus to date, no single strategy has proven beneficial for 
prevention of preeclampsia in either low risk or high-risk population. 
Since prediction and prevention of preeclampsia and eclampsia is 
still far away from becoming a reality, focus is still on treatment of this 
condition to optimize maternal and fetal outcome. 
Basic management objectives of any pregnancy complicated by 
preeclampsia are: 
(i) Termination of pregnancy with the least possible trauma to            
mother and fetus. 
(ii) Birth of an infant who subsequently thrives 
(iii) Complete restoration of health to mother 
The definitive treatment of women with preeclampsia and 
eclampsia is delivery. Along with use of antihypertensives  to decrease  
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BP, anticonvulsants are used  to  prevent   occurrence  or  reduce  the  
recurrence  of convulsions in women with severe preeclampsia and 
eclampsia respectively 39. 
OBSTETRIC MANAGEMENT OF SEVERE PREECLAMPSIA 
AND ECLAMPSIA 
The optimal obstetric management of severe preeclampsia and 
eclampsia is delivery of baby and placenta which alone reverses the 
condition at term gestation.  Depending upon maternal and fetal 
condition, delivery can be accomplished by induction of labour or 
caesarean section. The management of severe preeclampsia remote from 
term will depend on weighing the risks and benefits for mother and baby, 
after assessing fetal maturity.     
ANTIHYPERTENSIVES 
Antihypertensive treatment is usually given for diastolic BP 
>110mm Hg. Goal is to decrease diastolic BP to 90-100 mm Hg. 
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COMMONLY USED DRUGS 
DRUG DOSAGE 
ONSET 
OF 
ACTION 
DURATION 
OF ACTION 
ADVERSE 
EFFECTS 
MAX 
DOSE 
Parenteral  
Hydralazine 
5-10 mg 
IV q 20 
min 
10 -20 min 3-6 hrs Tachycardia, 
Headache, 
Flushing, 
Aggravation of 
angina 
60 mg 
Labetolol 20-80 mg 
IV q 10 
min 
5-10 min 3-6 hrs Flushing, Vomiting, 
Heart block 
300 mg 
Sodium 
nitroprusside 
0.25-
10µg/ 
kg/min IV 
 
1 min 1-2 min Nausea, vomiting, 
Thiocyanate  & 
Cyanide toxicity 
 
10µg/kg/ 
minute 
Nitroglycerine 5-100 
µG/min 
IV 
2-5 min 3-5 min Anemia, methHb, 
tachyphylaxis 
- 
Oral drugs 
Alpha methly 
dopa 
500 mg 
PO  
8 hrly 
2 – 4 hrs 12-24 hrs Sedation, lethargy 
Postural 
hypotension 
2 gm 
Clonidine 0.2 mg 
PO 
30 min 6-8 hrs Drowsiness, 
bradycardia 
1.2 mg 
Nifedipine 10mg PO 
q 30 min 
10-15 min 4-5 hrs Headache, syncope 
tachycardia 
120 mg 
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Nifedipine has become the main stay of treatment for hypertension 
in pregnancy.  It is a member of dipyridine class of calcium channel 
blockers and is practical, dependable and nonparenteral agent that is easy 
to administer and useful for acute as well as chronic administration. 
Nifedipine limits transmembrane influx of calcium into cardiac and 
smooth muscles. An unusual characteristic of the drug is that higher the 
BP, the further the decrease. In humans, nifedipine decreases the BP 
without any apparent decrease in uteroplaccental blood flow or change in 
fetal heart rate. Nifedipine and magnesium have synergistic effect causing 
neuromuscular blockage and hypotension40, 41. 
ANTICONVULSANTS 
           Magnesium sulphate has been used for treatment and prophylaxis 
of eclampsia and preeclampsia for more than 70 yrs. Alternatives to 
magnesium sulphate has been investigated including phenytoin and 
diazepam. The efficacy of magnesium sulphate in eclampsia and seizure 
prophylaxis for severe preeclampsia has been well studied and 
validated42.  
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HISTORY OF MAGNESIUM SULPHATE AS 
ANTICONVULSANT 
As early as 1906, magnesium sulphate was injected intrathecally to 
prevent eclamptic seizures by Horn 43. 
                  Rismann (1916) gave the drug subcutaneously 
                  Fischer (1916) gave the drug intravenously 
                  Lazard (1925) popularized the intravenous regimen44 
There were reports that IM magnesium sulphate controlled 
convulsions as with tetanus, a similar regimen was used in 1926 by 
Dorset to prevent seizures in women with eclampsia45.  
Eastman & Streptoe (1945)46 increased the dose of MgSO4 by 
giving an initial dose of 10gm IM followed by 5gm every 6 hrs.  
Pritchard (1955) & Chesley & Tepper (1957) combined the  
IV with IM dose. 
In 1993, the drug was given IV to hundreds of women at  
Los Angeles General Hospital. In all these studies, the dose of 
magnesium sulphate was small. 
 Later Pritchard47, Zuspan48 introduced IM regimen for 
magnesium sulphate. 
27 
PHARMACOLOGY OF  MAGNESIUM SULPHATE  
 MgSO4. USP is MgSO4.7H2O & not MgSO4 
 Its molecular weight is 246.5 
 1 gm of this salt contains 98 mg elemental Mg (10% of total 
weight) 
PHARMACOKINETICS OF MAGNESIUM SULPHATE  
            The pharmacokinetic profile of magnesium sulphate after IV 
administration can be described by a two-compartment model with a 
rapid distribution α phase and a slow β phase of elimination 49.   
Normal pregnancy level of Mg is 1.5-2.5 mg/dl.   
After administration, about 40% of plasma Mg is protein bound.  
A loading IV dose of 4-6 gm results in an immediate maternal plasma 
concentration of 5-9 mg /dl. This increase is transient and it falls to  
3-4 mg/dl within 60 minutes. Within 90 minutes about 50% of the Mg 
moves into bones and other cells50. Various authors showed that 
concentration of Mg in plasma rises gradually after IM injection within 
90-120 min, being the usual time to reach the maximum level in plasma51. 
This provided the basis for initiating treatment with IV dose. 
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Data from Sibai et al., suggests that levels are consistently 
1.7mmol/L using a regimen of 1g/hr (used in collaborative eclampsia 
trial). In contrast, Mg level ranges from 1.7 - 3.3 mmol/L with the 2g/hr 
maintenance infusion. Pritchard suggested a level of 2 - 3.5 mmol/L and 
1.8 -3.0 mmol/L as satisfactory for women with severe preeclampsia  
and mild preeclampsia respectively. Therapeutic level is between  
2-4 mmol/L52. 
Mg is excreted almost exclusively in the urine. About 50% of the 
infused dose is excreted in urine after 4 hours and 90% of the dose during 
first 24 hours after an IV infusion of magnesium sulphate. In presence of 
oliguria or significant renal failure, the maintenance dose should be either 
decreased or discontinued and Mg level to be monitored carefully. 
MECHANISM OF ACTION 
          The exact mechanism by which Mg protects against seizures has 
not been established but the prophylactic and therapeutic benefits of Mg 
are likely due to its ability to counteract vasospasm. Magnesium has both 
central and peripheral actions. 
(i) It causes depression of central nervous system (Borges and  
Gucer, 1978). 
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(ii) Increase in plasma Mg inhibits acetylcholine release in response to  
motor nerve impulse, decreases motor end plate sensitivity to 
acetylcholine and decreases motor end plate potential  
(Filmy & Soomjum).  
These actions do not account for controlling convulsions in 
eclampsia. 
(iii) Magnesium sulphate is an N methyl D aspartate receptor 
antagonist. Anticonvulsant action of magnesium sulphate is 
attributed to blocking calcium   influx through NMDA – subtype of 
glutamate channel53 (Lipton & Rosenberg 1994). 
(iv) Magnesium sulphate acts by opposing the calcium dependent 
arterial vasoconstriction.  It causes cerebral vasodilatation, and 
increases cerebral blood flow. 
(v) Protects endothelial cells from injury mediated by free radicals. 
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REPORTED BENEFICIAL EFFECTS 
 Decreases systemic vascular resistance & mean arterial pressure. 
Increases cardiac output (Cotton, 1984)          
 Increases uterine blood flow (Harbert, 1969) 
 Increases renal blood flow 
 Increases prostacyclin release (Watson et al) 
 Decreases platelet aggregation (Watson et al) 
 Decreases plasma renin level 
 Decreases angiotensinogen converting enzyme level 
 Attenuation of vascular response to vasopressors 
 Bronchodilation 
REPORTED DETRIMENTAL EFFECTS 
 Decreases uterine activity and prolonges labour 
 Decreases fetal heart rate variability (Atkinson, 1994) 
 Increases blood loss after delivery 
 Respiratory depression (Guzman et al) 
 Low apgar score 
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Magnesium sulphate is the ideal drug with rapid onset of action, 
non sedative effect on mother and baby,  fairly wide safety margin and 
readily available antidote. 
SIDE EFFECTS AND TOXICITY 
The effect and toxicity of magnesium sulphate can be linked to its 
concentration in plasma. The anticonvulsant effects of magnesium in 
clinically relevant doses do not involve depression of the neuromuscular 
junction.  
The first warning of impending toxicity in mother is loss of patellar 
reflex at plasma concentration between 9-12mg/dl 51.  
Other early signs and symptoms of toxicity include nausea, feeling 
of warmth, flushing, somnolence, double vision, slurred speech and 
weakness. Respiratory paralysis occurs at 15-17mg/dl.  
Cardiac arrest can be expected at a concentration of 30-35 mg/dl54. 
Careful attention to monitoring guidelines can prevent toxicity. Deep 
tendon reflexes, respiratory rate, urine output and serum concentrations  
are  most  commonly  followed valuables with magnesium sulphate use. 
Laryngeal reflexes are usually intact which protects against aspiration 
pneumonitis. Injection abscess can occur with IM route. 
             It is important to keep an ampoule (1gm) 10 ml of 10%  calcium 
gluconate  at  bedside  to  be  used  in case  of  toxicity. 
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CONTRAINDICATION 
             There exists no absolute contraindication except myasthenia 
gravis and heart block. 
EFFECT OF MAGNESIUM ON MOTHER 
Effect on cerebrovascular system  
Magnesium sulphate is a potent vasodilator, especially in cerebral 
vasculature and administration of magnesium sulphate to women with 
preeclampsia decreases intracerebral arterial spasm. Mg both in vivo55 
and in vitro56 increases production of endothelial vasodilator prostacyclin.  
Mg also protects against injury by free radicals to endothelial cells in 
vitro. 
Effect on cardiovascular system and respiratory system 
Pritchard found variable effect of magnesium sulphate on BP   
reported that anti hypertensive action was transient3. Hypotension has not 
been constantly produced by magnesium sulphate in management of 
preeclampsia. 
          Mg tends to decrease maternal respiratory rate in human subjects. 
There has been some reports that using magnesium sulfphate as tocolytic 
might be associated with pulmonary edema57. 
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Placental transfer 
Mg readily crosses placenta and fetal blood levels correlate well 
with maternal levels. Halleuk et al demonstrated demonstrable Mg level 
increase in fetal serum within one hour and amniotic fluid within three 
hours after maternal IV administration58. 
Uterine activity 
             Stallworthy found transient decrease in frequency of uterine 
contractions during magnesium sulphate loading dose but no significant 
change in intensity of uterine contractions60. 
Effect on FHR 
              The effect on fetal heart rate variability has been a controversial 
issue, as there is conflicting data in literature61. Atkinson et al using 
computerized fetal heart analysis concluded that magnesium sulphate is 
associated with objectively measured decrease in short term variability 
but the decrease was not clinically significant. There was no associated 
decrease in long term variability. 
Effect on newborn 
             An apparent depression in serum calcium levels have been 
reported in fetuses of mothers treated with magnesium sulphate62. Others 
have reported that Magnesium sulphate treatment does not cause neonatal   
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hypocalcaemia and that the induced neonatal hypomagnesaemia is 
resolved within the first 48 hours of life63. Although clinical neurological 
depression has been reported in newborn babies of women with 
preeclampsia treatment with magnesium sulphate, occurrence of adverse 
effect on offspring is quite rare64. There is no adverse effect on apgar 
score65, neonatal mortality or neonatal neurological assessment66 
EVIDENCE IN FAVOUR OF MAGNESIUM SULPHATE 
Observational studies on subsequent convulsions in women 
with eclampsia receiving magnesium sulphate. 
RECURRENT 
CONVULSIONS AUTHOR (YEAR) 
NO OF 
ECLAMPTICS 
No % 
Pritchard et al (1975) 85 3 3.5 
Ge dekoh et al(1981) 52 1         1.9 
Pritchard et al3(1984) 83 10        12.0 
Dunn et al (1986) 13 5         38.5 
Domisse et al67(1990) 100 3         3 
Sibai et al(1992) 315 41 13.0 
All studies 648 63        9.7 
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These studies paved way for the use of magnesium sulphate in 
eclampsia for preventing recurrence of convulsions. Various dosage 
regimens were followed in order to obtain an optimum therapeutic level 
of magnesium in blood.                                                  
In 1995, a study dubbed as the most important obstetric 
randomized trial of the 20th century showed that, of the three common 
approaches to controlling eclamptic convulsions, magnesium sulphate 
was most effective. The Collaborative eclampsia trial4 was a landmark 
in various aspects. The participation of 1687 women in 27 hospitals in 
developing countries, achieved more than all the small scale poorly 
controlled investigations over 50 years, mainly in countries where only 
1% of world’s cases of eclampsia occur. 
                                                    MgSO4 vs phenytoin 
              1680 eclamptics            
                                                   MgSO4 vs diazepam 
Outcomes analyzed were recurrence of convulsions and maternal 
death. Magnesium sulphate in the trial was administered either IV or IM. 
The Collaborative group showed that women allocated MgSO4 had 
52% lower risk of recurrent convulsions as compared to diazepam; 67% 
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decreased risk compared to phenytoin. Maternal mortality was non 
significant in both groups. Women allocated to MgSO4 were less likely to 
be ventilated, develop pneumonia or to be admitted in ICU as compared 
to women who received phenytoin. The babies of women given 
Magnesium sulphte were less likely to be intubated. 
Randomized controlled trials evaluating the use of 
magnesium sulphate in eclamptics 
INCIDENCE OF 
RECURRENT SEIZURES AUTHOR (YEAR) 
MgSO4 OTHERS 
Domisse 67(1990) 0/11 4/11 
Crowther68 (1990) 5/24 7/27 
Bhalle et al69(1994) 2/45 11/45 
Freidman et al70 (1995) 0/11 2/13 
Collaborative eclampsia trial4 60/43 126/452 
Collaborative eclampsia trial4 22/388 66/387 
 All studies          88/932 216/935 
 9.4% 23% 
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              The above studies further validated the fact that magnesium 
sulphate was better than other agents (like phenytoin, diazepam) in 
preventing recurrence of convulsions. 
Studies also showed that magnesium sulphate can also be used as 
prophylaxis in patients with severe preeclampsia to prevent occurrence of 
convulsions. 
The MAGPIE trial5 which involves 10141 women with 
preeclampsia and their carrers in 175 hospitals in 33 countries proved to 
be a landmark trial which showed that magnesium sulphate decreases the 
risk of eclampsia in women with preeclampsia. Women allocated to 
magnesium sulphate had 58% reduced risk for eclampsia. Women 
administered magnesium sulphate had 24 % side effects compared to 5 % 
in placebo group. Although very few side effects were life threatening, 
most of them were unpleasant and many experienced multiple side 
effects. Maternal mortality rate was also reduced in women allocated to 
magnesium sulphate. 
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Randomized Controlled Trials of Magnesium Sulphate in Severe   
Preeclampsia 
RATE OF SEIZURES 
MgSO4 Control AUTHOR 
No % No % 
Odendaal & Hall71(1996) 2/510 0.4 3/491 0.6 
Moodley&Moodley72(1994 1/112 0.9 0/116 0 
Coetzee  et al73(1998) 1/345 0.3 11/340 3.2 
 Magpie trial group5(2002) 40/5055 0.8 96/5055 1.9 
 Belfort et al 7/831 0.8 21/819 2.6 
       Total 49/6343 0.6 128/6330 2.0 
 
 The consistency of results further strengthens the case for 
magnesium sulphate. The best evidence in generating health care 
recommendation arises from meta analysis of randomized control trial 
without  heterogenecity .This was validated in a study by Villar et al, 
200474which compiled the  evidence from nine randomized controlled 
trials and concluded that magnesium sulphate was effective in preventing 
convulsions in women with eclampsia and severe preeclampsia.  
We now have undisputed evidence that magnesium sulphate is 
useful in women with severe preeclampsia and in eclampsia. 
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The magpie trial follow up study by Duley L et al(2007)75 has 
followed up 4782 women originally recruited to the study at the end of 
two years and concluded that magnesium sulphate was not associated 
with excess of death or disability for women after two years. 
                Another study by Dudley C et al(2007) 76  has successfully 
followed up 4483 children born to mothers who were recruited in the 
Magpie trial at the end of 18 months and concluded that magnesium 
sulphate was not associated with any clear difference in risk of death or 
disability for children at 18 months. 
LOW DOSE MAGNESIUM SULPHATE  
With substantial evidence to say that magnesium sulphate is choice 
for preeclampsia and eclampsia and its apparent safety, it was hoped that 
magnesium sulphate would be used invariably in above situation but the 
fear of fatal toxicity of respiratory depression in women who are much 
smaller than western women and in institutions where serum Mg 
monitoring is not feasible, magnesium sulphate is still used with some 
reluctance. 
The next research question obviously was “what is the minimum 
effective dosage?”  
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Because of the small size of Bangladesh women and concern about 
toxicity in circumstances where measuring Mg level would be difficult, a 
study was conducted in Bangladesh to test the efficacy of low dose 
regimen of magnesium sulphate. 
             The objective of study was to record the efficacy of low dose 
“Dhaka regimen” in preventing the recurrence of convulsions in 
eclamptic patients and to identify whether toxicity occurs with this dose 
(Begum et al 2001)6.The study included 65 eclamptics receiving low 
dose magnesium suphfate regimen - 10gm loading dose followed by 
2.5gm IM given 4th hourly for 24 hours after the administration of the 
first dose. Patients were monitored by observing for respiratory rate, deep 
tendon reflex and urine output. Findings were matched with serum Mg 
levels. Range of serum Mg was 1.74- 6 mg/dl. Five patients had 
diminished knee jerk with serum Mg within the therapeutic range 3.5 
mg/dl indicating increased sensitivity of women with smaller BMI. They 
concluded that half the standard dose of magnesium sulphate appeared to 
be sufficient to control convulsions. It has also been observed that serum 
concentration of drug is higher during treatment with maintenance 
regimen in patients with a lower body volume.  
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             Contrary to this, Phurapradit et al 77 found that mean serum Mg 
levels were significantly lower in women having a weight >70 kg than 
levels observed in patients with weight <70 kg. 
Similar study was conducted in India by Sardesi Suman et al 
(2003)78 in 1060 women (580 eclamptics & 480 imminent eclampsia) 
reported that eclamptic convulsions were controlled in  91.93% women 
and recurrence rate was only 7.84% . It  also showed that magnesium 
sulphate was 98.75% effective as seizure prophylaxis in imminent 
eclampsia. 
Shiva et al(2007)79 conducted a study in  50 eclamptic women 
comparing Pritchard regimen versus low dose magnesium sulphate 
regimen and reported a recurrence rate of only 4%. 
Since the introduction of low dose regimen the maternal mortality 
rate has fallen from i6% to 8% in Bangladesh(Begum et al 2000)80 
Comparison of Low dose regimen with the Pritchard’s regimen 
Patient outcome 
Sardesi et al 
Low dose regimen 
Pritchard et al 
Std  regimen 
Recurrence rate 7.89 % 9.7 % 
Maternal mortality 2.63 % 5.2 % 
Failure rate 0.18 % 1.5% 
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              These results show that low dose regimen is effective in 
controlling eclamptic fits and their recurrence, with the added advantage 
of reduced toxicity both in mother and newborn.  
              The average maternal weight in India is lower compared to 
western counterpart (45 kg vs 65 kg). In this situation, it is appropriate to 
reduce the dose of magnesium sulphate in Indian women because of their 
lower body weight and thus lower intravascular distribution of drug. 
LOADING DOSE OF MAGNESIUM SULphATE 
             Researchers in Bangladesh with low dose regimen of magnesium 
sulphate went one step further to test the efficacy of only the loading dose 
of magnesium sulphate in preventing seizure recurrence in women with 
eclampsia. 400 women were randomized with either loading dose or low 
dose regimen of magnesium sulphate. Recurrent convulsions were almost 
similar in both groups81. 
Loading dose 
N= 202 
Low dose  
N= 191 Patient outcome 
No % No % 
P value 
Recurrent 
convulsions 
8 3.96 7 3.52 ns 
Maternal death 9 4.45 10 5.02 ns 
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AIMS AND OBJECTIVES 
OBJECTIVES 
To compare Low dose ‘Dhaka’ regimen vs Standard Pritchard’s 
regimen of magnesium sulphate in patients with severe preeclampsia and 
eclampsia. 
AIMS 
(i) To determine if low dose of magnesium sulphate will be sufficient 
in preventing onset of convulsions in women with severe 
preeclampsia and prevent recurrence of convulsions in patients 
with eclampsia.  
(ii) To determine if clinical signs and symptoms of magnesium toxicity 
are less common in women with low dose regimen as compared to 
Pritchard’s regimen. 
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MATERIALS AND METHODS 
TYPE OF STUDY  
           Randomized controlled trial 
PERIOD OF STUDY  
            August 2007 - August 2008 
SETTING  
           The study was conducted at Institute of Obstetrics and 
Gynaecology, Chennai.  The study was approved by the board of Ethical 
Committee.     
DETERMINATION OF SAMPLE SIZE 
            The Magpie trial reported that adverse effects in Pritchard 
regimen of  magnesium sulphate was 25% and low dose ‘Dhaka’ regimen 
study was nearly 10%. In order to show the magnitude of difference in 
adverse effects with 95% confidence & 80% power, the sample size in 
each group was 100 women. 
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METHODOLOGY 
SCREENING  
All patients coming to the casualty with a provisional diagnosis of 
severe preeclampsia or eclampsia were screened for enrollment into the 
study. 
SUBJECT SELECTION CRITERIA 
Inclusion criteria 
(i) Patients with eclampsia 
(ii) Patients with severe preeclampsia with any one of the 
criteria 
• Diastolic BP > 110mmhg ; Proteinuria  2+ and above 
• Preeclampsia with symptoms like headache, vomiting, 
decreased urine output, epigastric pain 
Exclusion criteria 
(i) Patients having received magnesium sulphate before coming 
to the hospital. 
(ii) Patients with preexisting seizure disorder, heart block or 
renal failure. 
(iii) Postpartum eclampsia with onset of convulsion >72hrs after 
delivery.   
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CONSENT  
Informed consent in the form of written consent was obtained from 
the patient or relatives (in situations where patient is indisposed) after 
explaining the procedure and the drug effects. 
Patients were randomly assigned to Group D or Group P using 
random block number tables. Group D was designated as the study group 
receiving the low dose (Dhaka) regimen and Group P was designated as 
the control group receiving the standard (Pritchard) regimen. Drugs 
including the loading dose and maintenance dose were packed in separate 
boxes and marked serially as 1-200. Investigator was blinded to identify 
contents of each box (either Pritchard or low dose regimen).  
TREATMENT REGIMEN 
GROUP D - Low dose (Dhaka) Regimen :  
Loading dose – 4g (20% solution) was given slow IV followed by 
3g (50% solution) IM each buttock. 
Maintenance dose – 2.5g (50% solution) IM every 4th hourly  
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GROUP P - Standard dose (Pritchard’s) Regimen 
Loading dose -  4g  (20% solution ) was given slow IV followed by 
5g (50% solution ) deep IM each buttock 
Maintenance dose – 5g (50% solution) IM every 4th hourly  
A detailed history was obtained from the patients. General 
examination and obstetric examination was done.  Baseline parameters 
like height, weight, pulse rate, BP, respiratory rate, gestational age, fetal 
heart rate, bishop’s score and adequacy of pelvis were recorded. Initial  
resuscitation measures  were done and blood sample was obtained for 
routine investigation ( as per hospital practice/ guidelines) such as Hb, 
haematocrit, platelet count, S.bilurubin, SGOT, SGPT, S.urea, 
S.creatinine, S.uric acid, S.Fibrinogen and S.Electrolytes. Urinary bladder 
was catheterized and urine albumin recorded using dipstick method.  
PROTOCOL FOR ECLAMPSIA  
Patient was shifted to ICU and loading dose according to the 
treatment group assigned was given. Loading dose was administered 
irrespective of the urine output. Maintenance dose was continued for up 
to 24 hours postpartum or till 24 hours after the last seizure which ever 
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was later.  Pregnancy was terminated in all cases of eclampsia. 
Convulsions occurring 30 minutes after the loading dose or at any time 
later will be treated as recurrent convulsions. An additional dose of 2gm 
magnesium sulphate was given slow IV for recurrent convulsions. 
PROTOCOL FOR IMMINENT ECLAMSPSIA 
          Patient was administered the loading dose and maintenance dose 
according to the treatment group assigned. Maintenance dose was 
continued for 24 hours after the first dose. Decision regarding termination 
of pregnancy was done depending on the severity of the disease and 
maturity of the fetus. 
Antihypertensives in labour 
         If women were on antihypertensive, same was continued in labour. 
If diastolic BP >100mm Hg , Nifedipine 10mg was given 6th hourly. 
All patients were monitored on clinical criteria. Hourly monitoring 
of pulse rate, BP, respiratory rate, urine output, deep tendon reflexes was 
done. 
Maintenence dose of magnesium sulphate was withheld if signs of 
toxicity in the form of loss of deep tendon reflex, respiratory rate<16/min 
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and urine output (should be 25ml/hr or 100ml for last four hours) was 
found. If urine output was less than 25 ml/hr, dose was withheld and fluid 
challenge given. If urine output was adequate after the fluid challenge, 
dosage schedule continued.  10 ml of 10% calcium gluconate was kept 
ready in case of signs of toxicity. 
           Progress of labour monitored using partogram. Fetal heart rate 
monitored using intermittent auscultation or electronic fetal monitoring. 
Decision about optimal mode of termination of pregnancy was done by 
the consultants of respective units. 
OUTCOME 
(i)  Recurrence of convulsions in eclamptic patients. 
(ii) Occurrence of convulsion in preeclampsia patients. 
(iii)Side effects like flushing, nausea, vomiting, headache, thirst,  
            drowsiness, induration, abscess. 
      (iv)Toxicity like absence of deep tendon reflexes, respiratory 
  depression. 
       (v)Effects of magnesium sulphate on newborn. 
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                     RESULTS AND ANALYSIS 
This is a randomized trial comparing the efficacy of Low dose 
(Dhaka) regimen of magnesium sulphate with the Standard Pritchard’s 
regimen in patients with severe preeclampsia and eclampsia, conducted at 
the Institute of Obstetrics and Gynecology, Chennai during the period of 
April 2007 - April 2008 
200 women with severe preeclampsia and eclampsia were 
randomized to receive either the low dose regimen or the standard dose 
regimen. The results were subjected to statistical analysis using  
chi-square test. 
Table - 1 
AGE DISTRIBUTION 
Age in  yrs 
 
LOW DOSE 
(n = 100) 
STANDARD 
(n = 100) 
< 20 yrs 6 7 
20 -  30 yrs 91 84 
≥ 31 yrs 3 9 
Mean age 23.81± 3.64 23.92 ± 4.37 
                                                                                                                                                                                                                                (n= NO OF PATIENTS) 
     Both the groups were similarly matched with respect to their age 
group. The mean age group in Low dose regimen and Standard dose 
regimen was 23.81± 4.37 and 23.92± 3.64 respectively. 
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Table - 2 
PARITY 
PARITY 
LOW DOSE 
   (n =100) 
STANDARD 
  (n=100) 
PRIMI 63 65 
G 2 24 23 
G3 10 8 
G4 3 2 
G5 - 1 
G 6 - 1 
                                                                      (n= NO OF PATIENTS) 
Both the groups were similarly matched with respect to parity. Primis   
constituted 63 % cases   in the Low dose group and 65% in Standard dose 
group. 
Table – 3    
BOOKING 
BOOKING 
LOW DOSE 
(n = 100) 
STANDARD  
(n = 100) 
  BOOKED IN IOG 15 10 
 BOOKED OUTSIDE 67 70 
   UNBOOKED 18 20 
 
           Only 15 % cases in Low dose regimen and 10% cases in Standard 
dose regimen were booked in our hospital. 
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Table – 4   
EDUCATION 
EDUCATION
LOW DOSE 
(n =100 ) 
STANDARD   
( n =100 ) 
<  V   18 24 
  V  -  X 54 48 
  > X 28 28 
                                                                  (n= NO OF PATIENTS) 
Table - 5 
RELIGION 
RELIGION 
LOW DOSE 
(n = 100 ) 
STANDARD   
(n =100 ) 
HINDU 89 91 
MUSLIM 4 2 
CHRISTIAN 7 7 
 
TABLE - 6 
BODY MASS INDEX 
BODY MASS 
INDEX 
LOW DOSE 
REGIMEN 
STANDARD   
REGIMEN 
MEAN  BMI 26.20 ± 5.21 25.82±5.06 
 
         Both the groups were similarly matched with respect to education, 
religion & BMI. 
          The mean BMI in Low dose was 26.20 ± 5.21 and Standard dose 
was 25.82 ± 5.06 respectively. 
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Table   - 7 
BLOOD PRESSURE  
PARA METERS 
LOW DOSE
(n =100) 
STANDARD   
(n =100) 
DIASTOLIC BP >110mmHg 79 74 
ANTIHYPERTENSIVES IN   
PREGNANCY 
40 45 
                                                                                                                                                                                                    (n= NO OF PATIENTS) 
        - Both the groups were similarly matched   with respect to 
their Diastolic BP      
- 79 % patients in Low dose group and 74 % patients in 
Standard group had diastolic BP > 110mm Hg. 
- 40% patients in Low dose group and 45% patients in 
Standard regimen group were on antihypertensive therapy. 
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Table -8 
  IMMINENT SYMPTOMS 
SYMPTOMS OF IMMINENT 
ECLAMPSIA 
LOW DOSE 
(n =100 ) 
STANDARD  
( n =100 ) 
 HEADACHE 34 39 
 VOMITING 14 16 
  EPIGASTRIC PAIN 2 4 
 BLURRING OF  VISION 9 6 
DECREASED URINE OUTPUT 14 4 
                                                                                 (n= NO OF PATIENTS) 
- Most common imminent symptom was headache (34% in Low 
dose group compared to 39 % in Standard dose group) followed by 
vomiting (14 % vs 16 %). 
- 14% patients in Low dose group and 4% patients in Standard dose 
group had H/O decreased urine output. Loading dose of 
magnesium sulphate was given irrespective of urine output. The 
remaining doses were given if urine output was normal after fluid 
challenge . 
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Table -9      
RECURRENCE OF CONVULSION IN   ECLAMPSIA 
  
LOW DOSE 
(n=100) 
STANDARD  
        (n=100)  
NO OF ECLAMPTICS WHO 
HAD RECURRENT 
CONVULSIONS 
2 1 
NO OF EPISODES 1 1 
ADDITIONAL  MgSO4 
GIVEN 
2gm 2gm 
                                                                                                                                                                        
              P value > 0.05 - Not Significant.  
- Of the 41 eclamptic women recruited to the trial,  
3 developed recurrent seizures during the treatment period. 
-     2 patients in Low dose & 1 patient in Standard dose group. 
- All the 3 patients developed recurrent seizures in-between the 
dosage schedule. 
- These patients had only one episode of recurrence which was 
controlled with 2 gm magnesium sulphate given IV. 
- MgSO4 produced effective seizure control in  98 % in Low dose 
group and 99 % of patients in Standard dose group. 
- Recurrence rate of convulsions was 2% in Low dose group and  
1% in Standard dose group 
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Table – 10 
OCCURRENCE OF CONVULSION IN  SEVERE 
PREECLAMPSIA 
 
LOW DOSE 
(n=100) 
STANDARD   
(n=100) 
NO OF PATIENTS WITH 
SEVERE PREECLAMPSIA 
WHO HAD CONVULSIONS 
 
 
1 
 
 
1 
NO OF EPISODES 1 1 
ADDITIONAL  MgSO4  
GIVEN 2gm 2gm 
 
- Of the 159 severe preeclamptic patients recruited to trial,  
2 patients developed seizures during the treatment period. 
- 1 patient in Standard dose group developed seizures 2 hours 
after completion of dosage schedule & 1 patient in Low dose 
group developed seizures during the dosage schedule. 
-  The seizures were effectively treated with 2 gm magnesium 
sulphate. 
- Magnesium Sulphate was effective as seizure prophylaxis in 
99% in both groups. 
- Low dose magnesium sulphate was effective as Standard dose 
in seizure prophylaxis   in severe preeclampsia.       
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Table – 11 
SIDE EFFECTS 
SIDE EFFECTS LOW DOSE STANDARD   
 NO % NO % 
P  
VALUE 
FLUSHING 69/92 75 72/94 76.6 0.93 
NAUSEA/ VOMITING 10/92 10.9 15/94 15.9 0.42 
MUSCLE WEAKNESS 11/92 11.9 10/94 10.6 0.79 
THIRST 22/92 30.4 20/94 27.6 0.85 
DROWSINESS/ DIZZINESS 10/92 10.9 10/94 10.6 0.95 
PAIN/BURNING 50/92 54.3 58/94 61.7 0.38 
INDURATION 20/100 20 26/100 26 0.40 
ABSCESS 0/100  1/100 1 1.00 
   
SERIOUS MATERNAL TOXICITY LOW DOSE       STANDARD   
RESPIRATORY DISTRESS         0       0 
CARDIORESPIRATORY ARREST        0       0 
          P value  >0.05 -Not significant 
- 70% patients in Low dose group and 75% of patients in Standard 
group had at least one side effect. 
- 8% patients in Low dose group and 6% patients in Standard group  
were not able to evaluate early side effects because of low Glasgow 
coma scale. 
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- The most common side effect was flushing (75% in low dose group 
and 76.6% in standard group). 
- Pain was another common side effect because the maintenance 
dose was given IM (54.3% in Low Dose and 61.7% in Standard 
dose). 
- 10.9% patients in low dose group and 15.9% patient in standard 
group developed vomiting after the administration of magnesium 
sulphate. 
- 1 patient in standard group had injection abscess. 
- None of the patients had any serious maternal toxicity like 
respiratory distress. 
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TABLE - 12 
REASON FOR WITHOLDING MAGNESIUM 
SULPHATE 
REASON FOR 
WITHHOLDING 
MgSO4 
LOW 
DOSE 
(n=100) 
STANDARD 
(n=100) 
P VALUE 
LOSS OF DEEP TENDON 
REFLEX 
3 8 0.21 
OLIGURIA 2 4 0.61 
 BP NORMALISED 0 1 1.0 
CORTICAL VEIN 
THROMBOSIS 
0 1 1.0 
         P value >0.05  Not significant 
- 5 % patients in Low dose group and 14 % of patients in Standard 
group needed dose deferral. 
- Most common reason for withholding MgSO4 was loss of deep 
tendon reflex (3 % in Low dose group and 8% in Standard group ) 
- 2% patients in Low dose group and 4% patients in Standard group 
needed dose deferral due to oliguria inspite of fluid challenge. 
- 1 patient in Standard group had cortical vein thrombosis. This 
patient was shifted to intensive medical care unit for further 
management. 
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TABLE - 13 
COMPLICATIONS 
COMPLICATIONS 
LOWDOSE
(n=100) 
STANDARD 
(n=100) 
 VENTILATOR       2           3 
HELLP       0           3 
RENAL FAILURE       1           1 
CORTICAL VEIN 
THROMBOSIS 
      0             1    
PPH REQUIRING BLOOD 
TRANSFUSION 
      1           2 
          P value  >0.05 – Not significant 
- 2 patients in Low dose group and 3 patients in Standard 
group were put on ventilator due to low Glasgow score. 
- 3 patients in Standard group had HELLP syndrome. These 
patients were treated with platelets and  Inj. Betamethasone 
- 2 patients in Standard group and 1 patient in Low dose group 
needed blood transfusion for postpartum hemorrhage  
- We had one maternal death due to cortical vein thrombosis. 
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TABLE  - 14 
MODE OF DELIVERY 
 
LOWDOSE
   (n=100) 
STANDARD 
(n=100) 
P  
VALUE 
VAGINAL DELIVERY       44          42      NS 
CAESAREAN SECTION(CS)      53          55       NS 
MANUAL REMOVAL OF 
PLACENTA 
       0           1      NS 
             P -VALUE (NS-Not significant) 
- 44 % of patients in Low dose group and 42 % of patients in 
Standard group delivered vaginally. 
- The caesarean section rate was 53 % & 55 % in Low dose 
group and Standard group respectively. 
- 1 patient in Standard group had manual removal of placenta. 
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TABLE - 15 
INDICATION FOR CAESAREAN SECTION 
INDICATION FOR CS LOW DOSE STANDARD 
FETAL DISTRESS 18 24 
FAILURE TO PROGRESS 7 5 
ABRUPTION 4 4 
PREVIOUS LSCS 8 6 
BREECH 2 - 
FAILED INDUCTION 4 6 
LOW LYING PLACENTA 2 - 
DETERIORATING 
MATERNAL CONDITION 
4 5 
MULTIPLE PREGNANCY - 1 
UNFAVOURABLE CERVIX 4 4 
         P  Value  -  not significant 
- Most common indication for caesarean section was fetal distress in 
both groups (24 % in standard group compared  to 18%  in low 
dose group). 
- Failed induction & failure to progress were comparable in both 
arms. Hence higher dose of MgSO4 was not found to have tocolytic 
effect. 
- 6 patients had postpartum eclampsia (3 in each arm). All the 
patients had delivered vaginally - hence labor and delivery 
criteria’s were not analyzed for these patients. 
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TABLE – 16 
PERINATAL OUTCOME 
BABY DETAILS 
LOW 
DOSE 
STANDARD 
P 
VALUE
BIRTH WEIGHT 2.06± 0.76 2.05 ±  0.77 - 
STILL BIRTH 20 24 0.61 
NEONATAL DEATH 5 4 0.95 
REQUIRING NICU CARE 29 34 0.52 
RESPIRATORY DISTRESS 14 19 0.45 
HYPOTONIA 12 23 0.06 
APGAR  <  7 
        1 MIN 
        5  MIN   
 
30 
12 
 
44 
16 
 
0.06 
0.54 
          P value  > 0.05  - Not significant 
- The mean birth weight in  2.06 ± 0.76   in Low dose group 
and Standard group was 2.05 ± 0.77.      
- The still birth rate was almost similar in both arms (20 % in 
low dose group and 24% Standard group ). 
- Most of the still births were those occurring in women 
whose babies were nonsalvagable (weight < 1 kg / 
gestational age < 28 wks). Termination was done by   
vaginal PGE 1(misoprostol). 
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- 29 % in Low dose group and 34 % babies in Standard group 
needed NICU care . 
 - A higher number of neonates had hypotonia in Standard 
group than the Low dose group (23% vs 12%), but the result 
was  not statistically significant. 
-       30% of babies in Low dose group and 44% babies in Standard 
group had one minute apgar < 7. 
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TABLE – 17 
POSTNATAL DATA 
POSTNATAL DATA 
LOW DOSE 
   (n=100) 
STANDARD 
(n=100) 
P 
VALUE 
PATIENTS ON 
ANTIHYPERTENSIVE 
DURING DISCHARGE 
16 15 NS 
DURATION OF STAY 10.87 ±5.04 10.51±4.83 NS 
             P value -  NS  - Not significant 
-  16 % patients in Low dose group and 15 %  of patients in 
Standard group were on antihypertensives during discharge. 
-  The average duration of stay  for patients in   Low dose 
group was  10.87±  5.04 and in Standard group was 10.51 ± 
4.83 .   
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DISCUSSION 
          There is ample evidence to show that magnesium sulphate is the 
anticonvulsant of choice in women with severe preeclampsia to prevent 
onset of convulsions and to reduce the number of seizures in patients with 
eclampsia.  
              Inspite of various evidences proving magnesium sulphate to be 
safer drug, it is still used with reluctance in peripheral hospitals because 
of the fear of magnesium toxicity in the form of occasional respiratory 
depression in women who are much smaller than western women and 
where monitoring for serum Mg level is difficult. 
             This study was conducted to see if a lower dose of magnesium 
sulphate will suffice in our women in reducing the occurrence or 
recurrence of convulsions and to see if side effect and toxicity of Mg was 
less with the lower dose. 
The study was a randomized double controlled trial conducted in a 
tertiary institute. 200  women with severe  preeclampsia and eclampsia 
were randomized to  receive either the low dose (Dhaka) regimen  or 
Pritchard,s dose  regimen for magnesium sulphate. The randomization 
was done using a Tippet table. The researcher, patient & medical 
personnel administering the drug and assessing the side effects were 
blinded to the contents of the pack (either Low dose /Pritchard’s). 
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The results of this study are discussed as follows: 
In comparison of Dhaka regimen with Pritchard’s , the groups 
generated by randomization were well balanced.  
In the study by Sardesi Suman et al assessing the efficacy of Low 
dose regimen of MgSO4 among   eclamptic and preeclamptic women,  
majority of patients were in the age group 20 -30 years.  In our study too 
majority of our patients were in the same age group (TABLE - 1). 
At trial entry 64 % of women were in their first pregnancy 
comparable to study by Sardesi Suman et al where 66.3% of women 
were in their first pregnancy. (TABLE -2) 
In the study by Suman et al the average weight of women in the 
trial group was 48.4 kg. In our study   the   average weight of women was 
50.2kg (TABLE-3). 
Among the imminent symptoms headache was the most common 
symptom (39 % in Standard group vs 34% in Low dose group) followed 
by vomiting (16 %    vs   14 %) (TABLE -8).  This is comparable  to 
study by   Suman et al  which  showed  headache ( 54.57% )  & vomiting  
( 26.88% )  to be the most common imminent symptoms .  
Pritchard et al and Sibai showed a recurrence rate of 10 -20 using 
the Pritchard’s regimen. 
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Collaborative Eclampsia trial showed a recurrence rate of  
5.7– 13.2%.  
          In this study (Table 9) the convulsions were effectively controlled 
in   99% in Standard regimen and 98 % in Low dose regimen.  
The recurrence rate of seizures using low dose regimen was 2% in 
this study.  All the three  patients had only one recurrent convulsion 
which was controlled with 2 gm of Mgso4.  
This proved that Low dose regimen was as effective as Standard 
regimen in seizure control in eclamptics, though the results were not 
statistically significant. 
The seizure control rate using Low dose regimen from various 
studies were comparable to our study  
AUTHOR  (YEAR ) 
Convulsions 
controlled effectively 
Recurrence rate 
Sardesi Suman et al (2003) 91.93% 7.89% 
Begum et al (2001) 98.46% 1.5% 
 Shiva et al (2007) 96 % 4% 
Our study (Table - 9) 98% 2% 
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      In this study, (Table 10) among the patients with severe 
preeclampsia Low dose Mgso4 proved to be a  effective seizure 
prophylaxis  in 99 % of patients similar to that  in Standard 
regimen.  The failure of prophylaxis was 1 %. 
              Sardesi Suman et al showed Low dose MgSO4 to be 98 .75 % 
effective as seizure prophylaxis. The failure of prophylaxis was 
1.25 %. 
       In our study (Table 11) 75% of patients in standard dose group 
and 70% patients in Low dose group experienced at least one 
unpleasant side effect. This was in contrast to the MAGPIE 
TRIAL which showed only 25 % side effects for MgSO4 
compared to 5 % in placebo arm. 
      The side effects were relatively low in the Low dose group in 
this study though it was not statistically significant. 
      The side effect profile in both arms were similar  
      The most common side effect was flushing which was 
comparable to side effect profile in MAGPIE TRIAL.  
   As the maintenance dose of Mgso4 was administered IM, pain 
and induration at the site of injection was noted. 
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       1% patient in Standard group and none in Low dose group had 
injection abscess, which was reported in the Collaborative 
Eclampsia Trial. 
       In our study (Table 12) Magnesium sulphate was withheld in 
14% patients in Standard dose group and 5 % in Low dose group.  
      Most common cause for dose deferral was loss of deep tendon 
reflexes (8% in Standard group and 3 % in Low dose group). 
Though the dose deferral was high in the Standard group, the result 
was not statistically significant. 
The toxicity profile of this study was comparable to two studies : 
1) In a study by  Shiva et al (2007)  32%  needed dose deferral 
due to loss of deep  tendon reflexes  in Standard group as 
compared  to 8% in Low dose group. 
2) In a study by Begum et al (2001) 9% needed dose deferral 
due to Loss of  deep tendon reflex using Low dose regimen. 
           None of the patient had respiratory depression since strict 
clinical criteria for withholding MgSO4 was used. None of the 
patients needed calcium gluconate.  This was comparable to studies 
by Begum et al (2001) & Shiva et al (2000) using  Low dose 
regimen. 
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         42% women in standard group and 44 % women in Low dose 
regimen delivered vaginally (Table – 15). 
        Caesarean section rate in this study was 55 % in Standard 
group & 53% in Low dose group.  The most common indication 
was fetal distress in both arms. 
       The indication for caesarean section (Table -16) was similar in 
both arms. This showed that there was no apparent tocolytic effect 
of MgSO4 due to higher dose. 
          The still birth rate (Table – 17) in this study was 24% in 
Standard group and 20% in Low dose group. Most of the still births 
occurred in fetuses considered nonsalvagable in our hospital 
(weight < 1 kg or gestational age < 28 weeks). Termination was 
done using misoprostol. This was comparable to study by Shiva et 
al (2007) which showed a still birth rate of 32% in Standard group 
compared to 28 % in Low dose group. 
          In this study a higher number of neonates in Standard group 
had hypotonia (23%) when compared to Low dose group where 12 
% of neonates had hypotonia but this was not statistically 
significant. This was comparable to study by Shiva et al (2007) 
which showed 28% neonates in standard group had hypotonia 
compared to 4% in low dose group. 
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           The sample size in this study may have been insufficient to 
detect minor difference which exists between  the two drug 
regimen in terms of incidence of side effects or recurrence of  
convulsions, but these minor differences may not have clinical 
implications . 
            The incidence of recurrent convulsions in eclamptic women 
and occurrence of convulsions in severe preeclamptic women were 
comparable in both Pritchard’s and Dhaka regimen. From this 
study low dose regimen may suffice in our patients but the sample 
size is too small to bring out minor differences. 
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SUMMARY 
¾ Majority of women recruited to the study were in age group of   
20 - 30 years. 
¾ 65% patients in Standard dose group and 63% patients in Low dose 
group were primi gravida. 
¾ Low dose magnesium sulphate was effective in preventing 
recurrence of convulsions in 98% of patients. Recurrence rate of 
convulsions using low dose regimen was 2%. 
¾ Low dose regimen was effective as seizure prophylaxis in 99% 
patients. Failure of prophylaxis using low dose regimen was 1%. 
¾ 75% in Pritchard’s regimen and 70% patients in Dhaka regimen 
experienced side effects. Most common side effect was flushing.  
¾ None of the patient recruited had any serious maternal toxicity like 
respiratory depression.  
¾ 14% patients in Pritchard’s regimen and 5% patients in Dhaka 
regimen needed dose deferral. Most common cause of dose deferral 
was loss of deep tendon reflex. 
¾ 23% babies in Pritchard’s regimen and 12% babies in Dhaka 
regimen had hypotonia. 34% babies in Pritchard’s regimen and 
29% babies in Dhaka regimen needed NICU care. 
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                            CONCLUSION 
This study comparing the efficacy of a low dose ‘Dhaka’ regimen 
of magnesium sulphate to the standard Pritchard’s regimen showed that 
1)  Magnesium sulphate is a safe anticonvulsant with very less 
toxicity and side effect. Side effect profile of  Low dose ‘Dhaka’ 
regimen were similar to the Standard Pritchard’s regimen. 
2) Low dose regimen of magnesium sulphate is effective in 
preventing the recurrence of convulsion in women with eclampsia 
and preventing occurrence of convulsion in women with severe 
preeclampsia and the efficacy is similar to that of  the standard 
Pritchard’s regimen.  
3) Low dose regimen is a cost effective  regimen which can be safely 
used in peripheral hospitals and public health centres . 
4)  Implication for further research would be to test what the minimum 
effective dose would be and to see if only loading dose is 
sufficient. 
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PROFORMA 
 
NAME  :  IP NO. :  
AGE  : 
TYPE OF ECLAMPSIA  ; 
TYPE OF REGIMEN  : 
DOA  : 
RELIGION  : 
EDUCATION  : 
OBSTETRIC HISTORY  
a) Total no of pregnancies  :  
b) Any preeclampsia in prior pregnancy: 
c) Outcome of last pregnancy : 
PRESENT PREGNANCY: 
a) Last Menstrual Period  :  Expected due date : 
b) Period of gestation   
c) Prior  Antenatal visits  : 
d) No of Antenatal visits  : 
e) Any high BP in prior visits  : 
f) Any treatment taken  : 
g) Any other medical complication  : 
h) Any treatment taken for medical disease: 
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ECLAMPSIA DETAILS: 
a) Type of eclampsia: b) Date :                        
c) Time:                          d) Place: 
e) No of episodes: f)  Any treatment  before admission: 
EXAMINATION AT ADMISSION: 
a) General condition: b) Height  c)  Weight                               
d) BMI: e) Pulse rate: f)   BP:  
g) CVS & RS: h) Pallor:  i)  edema: 
j) jaundice: 
OBSTETRIC EXAMINATION: 
            a)  Per abdomen : 
            b)  Per vaginal : 
LABOUR: 
          a) Onset-     i)spontaneous                    ii)induced 
          b) Method of induction: 
          c) Mode of delivery : 
          d) Indication for CS: 
          e) Outcome : 
COMPLICATION DURING LABOUR/ DELIVERY : 
 a) Prolonged labour b) Abruption 
 c) PPH d) Rtained placenta 
 e) Genital injury f) Postpartum  shock   
89 
INVESTIGATION : 
 a) Hb: b) PCV: c) Platelets: 
 d) Urea: e) Creatinine: f) SGOT: 
 g) SGPT: h) Electrolytes: i) Urine albumin : 
 j) Fundus :                                                                
NEONATAL RECORD: 
 a) Sex : b) Birth weight: c) Maturity:   
 e) Apgar score: f) congenital anomalies:  
 g) Condition of baby at birth:       
CONDITION AT DISCHARGE : 
a) Total dose of MgSO4 given: 
b)  No of recurrent convulsions 
c) Was any other drug given  to control convulsions: 
d) Was the arranged regimen changed due to any reason: 
e) If yes, specify reason: 
f) Did mother have any signs of toxicity: 
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GLOSSARY 
Mg               -        Magnesium  
AFP             -        Alpha Feto Protein  
BMI            -         Body Mass Index  
BP               -         Blood Pressure 
 β HCG       -         Beta Human Chorionic Gonodotropin 
CS              -          Caesarean section      
IUGR         -          Intrauterine growth Retardation  
LDH           -         Lactate Dehydrogenase     
MgSO4           -          Magnesium sulphate   
NICU         -          Neonatal intensive Care Unit 
PCV           -          Packed Cell volume    
PPH           -          Postpartum Haemorrhage       
SGOT        -          Serum Glutamate Oxaloacetate Transaminase 
SGPT         -         Serum Glutamate Pyruvate Transaminase  
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FIGURE– 1 
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                                                                                              EDUCATION 
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BODY MASS INDEX 
 
 
25.6
25.7
25.8
25.9
26
26.1
26.2
Body Mass Index
standard Low Dose
 
 
 
 
 
 
 
95 
 
 
 
 
 
 
 
BLOOD PRESSURE PARAMETERS 
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IMMINENT SYMPTOMS 
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FIGURE - 9 
RECURRENCE OF CONVULSIONS 
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FIGURE– 11  
SIDE EFFECTS 
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        I            - INDURATION 
                                                                Ab        - ABSCESS  
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FIGURE -13 
COMPLICATIONS 
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FIGURE - 14 
MODE OF DELIVERY 
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FIGURE - 15 
INDICATION FOR CAESAREAN SECTION 
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PERINATAL OUTCOME 
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1 Kamatchi IE std dose 24 II HI BO 19.6 10 PRIMI 40 Y 140/100 3+ H,BV F,P,V,T Y CS FP A 2.75 7,8
2 Fathima IE std dose 21 X M BO 30.8 6 G2A1 27 Y 160/120 2+ F,M Y LN SB 1.5 -
3 Maheswari IE std dose 24 II HI BI 23.4 5 G2P1L1 38 Y 130/100 2+ Y LN A 2.4 8,9
4 Jayalakshmi IE std dose 21 XII HI B0 20 7 PRIMI 34 Y 170/110 4+ H F,P,I Y LN SB 1.2 -
5 Meera IE std dose 25 III HI BO 22.2 13 G2P1L0 35 140/100 4+ H,BV CS FD A 1.8 4,6 hypotonia y
6 Jilani IE std dose 29 XII M BO 40.8 12 G2P1L0 38 Y 150/120 3+ H F,P,I CS Abrubtion A 3.7 3,6
7 Pandeswari IE std dose 20 II HI BO 22.6 12 G3P2L1 30 140/100 1+ E F,V,P,T CS P.CS A 1.3 6,7 hypotonia y
8 Sheela IE std dose 22 XII HI BO 35.13 3 G2P1L1 34 Y 160/90 3+ H,V F,P,I Y LN A 2..3 7,8
9 Komala IE std dose 32 III HI BO 21.3 5 G4P3L3 35 Y 150/100 2+ H F,T,M LN A 1.75 6,7
10 Varalakshmi IE std dose 27 XII HI BI 9 G5P4L1 39 Y 170/120 2+ H Y LN A 2.6 5,7
11 Koteswari IE std dose 23 II HI BO 19.8 4 PRIMI 37 Y 120/90 4+ H F,P,I HELLP Y LN SB 1.5 -
12 Shakiladevi IE std dose 26 XII M BO 28.7 9 PRIMI 36 140/90 1+ H,V F,T LN A 2.8 7,8
13 Shakira IE std dose 37 V M BO 22.9 6 G3P2L1 32 Y 150/100 2+ H PPH LN SB 1.2
14 sharmila IE std dose 21 X HI BI 41.4 19 PRIMI 38 Y 170/110 3+ F,V,D CS Abrubtion SB 1.5
15 rajeshwari IE std dose 20 X HI BO 30.2 9 PRIMI 36 150/100 2+ H F,P,M CS FI A 2.75 7,8
16 sangeetha IE std dose 21 V HI UB 24.2 11 PRIMI 38 Y 140/100 4+ F,P,I ↓UO HELLP Y CS DMC A 2.1 5,6 Hypotonia, RD Y
17 devikala IE std dose 21 X HI BO 22.7 12 PRIMI 40 Y 210/120 3+ V CS CX A 2.4 7.8
18 amsala IE std dose 21 V HI BO 25.7 12 PRIMI 38 Y 150/130 3+ F,V,T CS FD A 2.3
19 satya IE std dose 20 VIII HI BO 26.3 5 PRIMI 39 Y 160/110 2+ F,P,I,T LN A 2.5 7,8
20 kavitha IE std dose 20 V HI UB 23.1 6 PRIMI 30 170/110 4+ H,↓UO F,P,D LN SB 1
21 silambarasi IE std dose 23 II HI BO 20.8 5 G2P1L1 38 Y 180/110 2+ P,I LN A 2.5 6,8
22 gunasundari IE std dose 29 Gr HI BO 24.9 12 PRIMI 32 170/120 4+ H,V F,P LN SB 1.4
23 navanetham IE std dose 24 XII HI BO 22.8 10 PRIMI 40 Y 150/110 4+ H P ↓DTR CS FD A 2.5 7,8
24 famidha IE std dose 19 V M UB 5 PRIMI 28 170/130 2+ H F LN SB 1
25 latha IE std dose 28 X HI BO 23.8 10 G6P2L1A3 37 Y 150/120 4+ F,P CS P.CS A 2.5 7,8
26 parameshwari IE std dose 23 V HI UB 22.2 13 PRIMI 32 190/110 3+ H F,V,P,I,T CS Abrubtion A 1.75 5,6 Hypotonia,RD Y
27 radha IE std dose 20 XII HI UB 9 PRIMI 36 Y 180/120 4+ F,P,D CS FD A 2.9 7,8
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28 ramya IE std dose 22 Gr HI UB 41.3 8 PRIMI 30 170/140 4+ F,P CS FI A 1.5 5,6 Hypotonia,RD Y
29 lakshmi IE std dose 23 X HI UB 9 G2A1 30 180/120 4+ ,V,BV,↓UO CS DMC E 1 6,7 Hypotonia,RD Y
30 meena IE std dose 23 X HI BO 29 14 G2P1L1 40 180/130 2+ H F,M CS FP A 1.6 7,8 hypotonia RD Y
31 jeeva IE std dose 20 V HI UB 21.2 9 PRIMI 41 140/100 1+ H,V F,P,I CS FD A 2.9 7,8 RD Y
32 anandhi IE std dose 30 VIII HI BO 38.9 11 PRIMI 22 Y 180/140 3 F,P,I MRP LN SB 0.6
33 vidyalatha IE std dose 33 V HI BI 18 22 G2P1L1 35 Y 200/100 1 V F,T Y CS P.CS A 1.25 6,7 IUGR Y
34 gomathy IE std dose 22 II HI BO 27.88 12 PRIMI 40 150/110 3 F,V,P,I LN A 2.8 7,8
35 thayar IE std dose 22 II HI BO 22 PRIMI 30 150/110 2 H,BV CS FI SB 0.5
36 thilagam IE std dose 24 XII HI BO 23.4 11 G2P1L1 40 Y 180/130 2 F,D LN A 1.75 6,8 hypotonia y
37 sujatha IE std dose 28 II HI BO 27.6 29 G2P1L1 33 180/130 3 F,V,P,T CS FI A 2.1 6,8 y
38 vijaylakshmi IE std dose 23 XII HI BO 24.3 8 PRIMI 40 150/110 1 H,E CS FD A 3.2 7,8
39 shameena IE std dose 19 X M UB 38.7 11 G3P1L1A1 35 Y 150/110 1 H F,V,P ↓UO CS P.CS A 2.8 7,8
40 vasantha IE std dose 21 V HI BO 23.4 5 PRIMI 40 Y 180/130 2 F,M,T LN A 2.25 7,8
41 valarmathy IE std dose 19 XII HI BO 26.7 12 PRIMI 31 140/100 4 H LN A 1.25 6,7 hypotonia,RD Y
42 vijaya IE std dose 35 III HI BI 29.5 8 G2P1L1 36 170/110 2 F,P,I,T ↓DTR CS P.CS A 2.25 7,8 Y
43 deivanjali IE std dose 26 XII HI BO 23.3 9 G3P2L2 40 140/110 4 H,V,E F,P,I LN A 1.6 7,8
44 poongodi IE std dose 26 X HI BO 30.8 10 G2P1L0 37 170/114 3 CS FD A 3 3,7 RD,Hypotonia Y
45 jyothilakshmi IE std dose 21 II HI BO 21.7 9 PRIMI 40 180/120 3 H F,P,I CS FD A 2.1 6,8 RD Y
46 kavitha IE std dose 21 UE HI BO 26.2 7 G3P1L1A1 40 Y 170/110 3 F,P,T PPH CS Abrubtion A 3 5,6 hypotonia Y
47 Shaira IE std dose 23 V M BI 26.2 5 PRIMI 38 Y 160/110 3 BP LN SB 1.6 -
48 devaki IE std dose 31 VIII HI BI 27.08 8 PRIMI 40 170/110 3 CS FD A 3.4 6,8
49 manimegalai IE std dose 27 III HI BO 25.8 19 G3P2L2 35 150/110 3 F,P LN A 1.5 6,7 hypotonia y
50 saroja IE std dose 20 V HI BO 28 12 PRIMI 36 Y 150/110 2 F,T CS FD A 2.2 7,8 y
51 jyothi IE std dose 32 X HI BO 20 G2PL1 36 170/110 3 F,P,M LN A 2.7 7,8
52 subhashini IE std dose 24 UE HI UB 27.6 10 G2P1L1 40 140/110 3 F,P,V CS FD A 2.1 6,8 hypotnia y
53 kala IE std dose 23 VIII HI BO 20.3 8 PRIMI 40 Y 160/120 3 F,P,V CS FD A 2.2 8,9 RD y
54 aprose IE std dose 35 X C BO 22 G4P1L0A2 33 180/120 4 CS FD A 1.25 4,7 RD,hypotonia y
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55 sasikala IE std dose 29 XII HI BO 25.9 8 PRIMI 38 Y 160/110 2 F,P,D ↓DTR CS DMC A 3.25 6,8
56 ezhilarasi IE std dose 24 VIII HI BI 23.2 13 G2P1L1 38 150/110 3 CS FD A 1.9 7,8 hypotonia,RD y
57 nadhiya IE std dose 24 XII HI BI 27.1 9 PRIMI 40 Y 170/120 3 F,P CS FD A 2.6 6,7
58 sumathi IE std dose 38 III HI BI 25.9 9 G2A1 38 Y 190/110 3 F,P,V CS FD A 2.7 6,8
59 swaroopa IE std dose 21 V HI B0 26.8 2 PRIMI 36 130/120 2 H,V F,P,I,A LN E 2.6 3,6 RD,hypotonia y
60 poongodi IE std dose 24 XII HI BO 29.4 7 PRIMI 37 140/110 3 CS CX A 3.5 7,8
61 ramani IE std dose 24 X HI BO 30 8 PRIMI 37 Y 170/110 1 H,V CS FD A 2.75 7,8
62 prabhavathy IE std dose 23 X HI BO 22.9 8 PRIMI 37 Y 190/130 4 H,V,BV F.P,I ↓DTR CS DMC A 2.4 3,7 RD,hypoyonia y
63 sumathi IE std dose 21 VIII HI BO 10 PRIMI 29 180/130 3 H,E F,V,P LN SB 0.75
64 kanaga IE std dose 24 UE HI UB 26.7 8 PRIMI 37 160/110 4 F,P,D CS FD A 2.3 8,9
65 bhuvaneswari IE std dose 25 X HI UB 5 PRIMI 29 150/110 4 F,P,I Y LN SB 0.6
66 karpagavalli IE std dose 25 V HI BO 20.2 18 PRIMI 36 170/120 2 F,M ↓UO RF CS FI E 1.2 4,7 hypotonia,RD Y
67 vasanthi IE std dose 22 VIII HI BO 25.5 13 PRIMI 39 Y 150/100 3 H,V LN A 2.7 6,7
68 bharathi IE std dose 25 III HI BO 30 3 G2P1L1 34 150/110 2 H F,P,I Y LN A 2.2 6,7
69 satya IE std dose 27 Gr HI UB 9 PRIMI 34 210/140 3 H,V,BV F,T Y CS FD A 2 6,7
70 ezhilarasi IE std dose 20 II HI BO 26.9 15 G2A1 34 150/110 4 HELLP,VENT CS DMC A 2 3,5 RD,Hypotonia Y
71 sudha IE std dose 18 X HI UB 13 PRIMI 34 140/110 3 H,V F,V,P ↓DTR CS P.CS A 3.25 6,8
72 uma IE std dose 28 X HI BO 34.2 7 G2P1L1 38 Y 150/110 3 H F,V CS FP A 3.25 6,7
73 alamelu IE std dose 22 Gr HI BO 22.8 8 PRIMI 40 160/110 2 H P LN A 1.75 6,8 y
74 malarkodi IE std dose 27 XII HI BO 23.7 16 G2P1L1 36 160/110 3 F,P,D ↓DTR LN A 1.8 6,8
75 shyamaladevi IE std dose 25 V HI BO 9 PRIMI 37 150/110 2 H F,T CS FD A 2.75 6,7
76 nisha IE std dose 22 X HI BO 26.8 8 PRIMI 36 150/110 1 H,V F,P,I CS FD A 2.6 6,8
77 lakshmi IE std dose 25 VIII HI BO 21 8 PRIMI 39 Y 150/120 3 V F,P,M Y CS FD A 2.4 6,8 IUGR Y
78 padma IE std dose 22 X HI BO 17 PRIMI 28 160/110 1 H,V,BV F,P,I LN SB 1 ,
79 vijajlaksnmi IE std dose 23 VIII HI UB 25.7 16 G3P1L1A1 39 170/120 4 H,↓UO F,P,T ↓DTR ONVULSION LN SB 1.5
80 usha IE std dose 27 Gr HI BO 28 8 PRIMI 40 Y 130/100 2 H CS CX A 2 5,6 RD Y
81 jayaprada AP std dose 20 Gr HI BO 25.6 19 PRIMI 37 170/120 4 F,P,V,T LN E 2.3 3,5 RD,Hypotonia Y
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82 selvi AP std dose 23 II HI UB 18.4 11 G2P1L0 28 130/104 3 - CONVULSIOENTILATOR CS FP A 2 4,6 Hypotonia,RD Y
83 durgadevi AP std dose 21 UE HI UB 18.4 14 PRIMI 28 140/100 4 F,P,D LN SB 1.5
84 dhatchayani AP std dose 20 X HI BO 22.3 10 G2P1L1 36 140/90 3 F,P,T ↓UO CS CX A 2 5,6 Hypotonia Y
85 devi AP std dose 24 VIII HI BO 24.2 22 PRIMI 37 190/130 2 H,E F,P,M,I CS TWINS A 2.1,/1.7 4,6 RD,Hypotonia Y
86 babitha AP std dose 22 XII HI BO 24.8 9 G2P1L1 39 Y 180/120 4 H F,P,T CS FP A 2.75 7,8
87 kanikakumari AP std dose 24 Gr HI BO 21.9 11 PRIMI 28 210/130 4 H,V LN SB 2.4
88 vimala AP std dose 19 XII HI BO 27.9 11 PRIMI 38 Y 170/110 4 VENTILATOR CS FD A 3.35 7,8
89 chandra AP std dose 21 X HI BO 19.2 9 PRIMI 38 Y 150/110 3 F,P,D,I CS FD A 3.5 7,8
90 nandhini AP std dose 20 X HI BO 19.2 5 PRIMI 27 Y 230/90 4 F,P,M Y LN SB 0.7
91 sasikala AP std dose 23 VIII HI UB 27.4 10 PRIMI 31 170/100 3 F,P LN SB 1.3
92 meena  AP std dose 18 Gr H UB 25 6 G2P1L1 28 150/100 3 F,P,D,I LN SB 1
93 janet AP std dose 39 VIII HI BO 23 8 G3P2L2 28 Y 150/100 2 F,P,I Y LN SB 1.6
94 Meera AP std dose 19 Gr HI B0 28.4 12 PRIMI 35 Y 160/110 3 F,P,I LN SB 1.6
95 manimegalai AP std dose 22 UE HI B0 26.6 11 PRIMI 33 160/110 4 F,T ↓DTR CS FI A 1.75 6,7 Y
96 banu AP std dose 21 XII HI UB 5 PRIMI 33 190/130 3 LN SB 0.45
97 reeta AP std dose 20 II C BO 26 11 PRIMI 22 200/120 4 LN SB 0.45
98 lakshmi PP std dose 22 UE HI BO 12 P1L1 Y 170/110 2 F,P,I LN A 1.8 6,7
99 navanetham PP std dose 24 VIII HI BO 11 P1L1 160/100 3 F,P CS A 2.5 7,8
100 saranya PP std dose 21 XII HI BO 20 P2L2 Y 150/100 2 CVT CVT CS A 1.8 5,6
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1 sumathi IE low dose 20 V HI BO 24.6 9 PRIMI 32 140/110 3 H,BV F CS Abruption A 1.2 6,7 hyopotonia Y
2 asha IE low dose 21 X HI BO 33.8 6 PRIMI 35 Y 140/110 2 H P,M,I LN E 2 3,6 Y
3 punithavalli IE low dose 30 II HI BI 29.2 10 G2P1L1 38 Y 180/110 2 H F,V,P,I CS P.CS A 2.75 7,8
4 reeta IE low dose 27 V HI BO 21 6 PRIMI 26 160/110 2 H,↓UO,E F,T LN SB 0.9
5 valarmathy IE low dose 22 II HI BO 40.4 11 PRIMI 39 Y 200/120 2 H,V F,D,P,T ↓DTR Y CS FD A 2.9 8,9
6 anushalini IE low dose 24 VIII HI OB 30 10 PRIMI 37 Y 130/100 2 LN A 2 7,8
7 khadeeeja IE low dose 22 V M B 25.3 7 PRIMI 33 150/120 4 F,P,I Y LN SB 1
8 shalini IE low dose 20 XII HI BO 24.8 10 PRIMI 38 Y 130/90 3 F,V,T Y CS FD A 3.1 7,8
9 ganasekhari IE low dose 27 VIII HI BO 27.8 8 PRIMI 34 170/110 2 H F,P,I CS FI A 2.85 7,8
10 malliga IE low dose 28 V HI BI 31.5 8 PRIMI 36 Y 140/110 2 BV CS B A 2.7 7,8
11 anitha IE low dose 19 X HI UB 24.2 9 PRIMI 40 140/90 1 H,V,BV,E P CS FD A 3.2 7,8
12 muthulakshmi IE low dose 24 V HI BO 29.2 20 PRIMI 32 140/100 1 H F,D,P,I LN SB 1.5
13 vijaya IE low dose 25 X HI BO 20.8 3 G2P1L1 38 Y 170/120 4 LN SB 1.5
14 revathy IE low dose 22 VIII HI BO 20.9 8 PRIMI 28 150/110 3 ↓UO F,M LN SB 1.1
15 jayapoorna IE low dose 29 V HI BO 34.7 11 PRIMI 28 160/100 4 F,D,T CS FI SB 1.2
16 yamini IE low dose 25 II HI BI 29.8 20 G2P1L1 35 140/100 2 H F,P CS P.CS A 3.1 7,8
17 maheswari IE low dose 22 VIII HI BI 26.1 9 PRIMI 39 Y 140/100 2 H,V F,P,I,T CS FD A 2.9 7,8 hyopotonia,RD Y
18 usha IE low dose 20 X HI BO 21.6 10 PRIMI 36 160/110 4 CS Ab A 1.7 4,6 Y
19 sulekha IE low dose 21 XII HI BO 37.3 11 PRIMI 34 170/120 2 F,M,P Y CS FD A 3 7,8
20 kiruba IE low dose 28 V HI BI 37.5 16 G2P1L1 26 130/100 4 F,V,D Y CS FP A 2.25 ,78
21 pavithra IE low dose 20 X HI BI 26.2 9 PRIMI 37 Y 150/90 2 LN A 2.7 7,8
22 kavitha IE low dose 22 XII HI BO 7 G3A2 33 170/100 3 H,↓UO F,P,T LN SB 0.5
23 madhavi IE low dose 28 VIII HI BI 32.4 22 G2P1L1 37 Y 160/100 4 ↓UO CS FI A 2.8 7,8
24 sasikala IE low dose 20 Gr HI BI 23.9 8 G3P2LI 37 170/110 3 H,BV F,P,I CS P.CS A 2.75 7,8
25 jayanthi IE low dose 29 XII HI BO 7 PRIMI 38 Y 150/110 3 H,V F,P CS FD A 1.6 6,8 IUGR Y
26 sangeetha IE low dose 18 VIII HI BO 20.9 8 PRIMI 32 180/120 4 H,↓UO F,P,T LN A 1.75 7,8
27 jayanthi IE low dose 30 XII HI BI 21.5 8 PRIMI 32 140/100 1 H,V F LN A 1.5 7,8 hypotonia Y
28 khadarbee IE low dose 20 V HI BO 23.9 7 PRIMI 39 Y 140/110 3 V F,P CS FP A 3.1 7,8
29 bhuvaneshwari IE low dose 23 XII HI BO 39 8 G2A1 32 Y 150/110 3 F LN A 2.5 6,7
30 vijaya IE low dose 28 UE HI UB 24.7 12 PRIMI 24 130/94 3 ↓UO F,V,M LN A 1.5 7,8
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31 thenmozhi IE low dose 28 X HI BO 24.7 18 G2P1L1 33 180/120 4 H,↓UO Y CS PP A 1.2 7,8 RD Y
32 bharathy IE low dose 23 XII HI BO 22.4 21 G2P1L1 35 150/110 4 F,P,I LN A 1.6 7,8 RD Y
33 subhashini IE low dose 23 V HI BI 24.4 12 G4P2L2A1 36 Y 180/130 2 ↓UO F,D,P CS FD A 1.6 5,6 RD Y
34 elavarasi IE low dose 23 II HI BO 26.9 12 PRIMI 32 130/110 4 H,V F,P,T LN SB 0.9
35 chithra IE low dose 30 X HI BO 34.6 5 G3P1L1A1 37 Y 130/110 3 H F LN A 2.9 7,8
36 sumathi IE low dose 30 V HI BO 30.8 12 G2P1L0 30 160/100 3 F,V,D LN E 1.4 3,5 hypotonia RD Y
37 usha IE low dose 20 X HI BO 21.6 21 PRIMI 36 160/110 4 F,P,T CS Abruption A 1.7 3,4 hypotonia Y
38 srividhya IE low dose 31 X HI BO 4 G2A1 30 150/110 3 H,V F,P,I LN SB 0.9
39 jennifer IE low dose 20 VIII C BO 24.8 12 PRIMI 38 Y 130/90 1 H,V CS FI A 1.8 7,8
40 latha IE low dose 25 XII HI BO 26 17 PRIMI 36 140/110 2 H F,V,P CS FD A 2.75 3,6 hypotonia Y
41 shanthi IE low dose 24 II HI BO 25.8 5 PRIMI 37 Y 180/150 3 H F,P,T LN FD E 1.5 6,7 IUGR Y
42 lakshmi IE low dose 19 V HI BO 27.6 17 PRIMI 36 200/110 1 H F,P,T CS B A 2.25 7,8 IUGR
43 pushpa IE low dose 26 XII HI BO 38.5 8 G2P1L0 37 Y 170/110 3 H,↓UO F,V,M ↓DTR CS FD A 2.4 6,7 RD Y
44 fathima IE low dose 23 II M BO 25.5 16 G2P1L1 36 170/120 2 H CS CX A 1.7 7,8 Y
45 kavitha IE low dose 23 V HI BO 28.6 8 PRIMI 40 150/110 2 CS FD A 3.4 5,8
46 anitha IE low dose 25 Gr HI BI 20.9 9 PRIMI 37 Y 140/120 3 H F,P,I CS FD A 2 7,8 RD Y
47 muniamma IE low dose 30 UE HI UB 24.4 11 G4P2L2A1 34 Y 170/120 3 H F,P,M CS PP A 1.6 6,7 RD
48 sangeetha IE low dose 23 XII HI BO 22.7 5 PRIMI 38 180/120 3 LN SB 0.9
49 vijaya IE low dose 23 V HI BO 25 4 G3P1L1A1 34 170/110 3 F,P,I LN A 1.6 7,8 Y
50 kavitha IE low dose 24 XII HI BI 31.5 6 PRIMI 33 Y 150/110 2 F,P,T LN SB 0.9
51 amudha IE low dose 26 II H BO 19.5 6 G2P1L1 30 180/130 2 LN SB 1.3
52 naveena IE low dose 33 X HI BI 38.8 9 G3P1L1A1 37 Y 150/110 3 H,V,BV F,M CS FD A 2.3 7,8 RD Y
53 pavithra IE low dose 21 XII HI BI 22.5 9 PRIMI 37 Y 160/120 1 H PPH LN SB 1
54 jayalakshmi IE low dose 22 VIII HI BO 22.9 20 G2P1L0 36 140/110 2 H,V F,P,I CONVULSION CS DMC A 1.8 5,7 Y
55 vanitha IE low dose 27 UE C UB 22 G2P1L1 35 Y 160/110 3 F,P CS P.CS A 2 6,7 Y
56 sobana IE low dose 27 XII HI BO 29.2 9 G3P1L1A1 36 170/120 3 ↓UO ↓UO CS DMC A 2.25 7,8
57 dharmeth IE low dose 36 X M BO 40.8 18 G2P1L1 37 Y 200/110 4 H F,P,I CS P.CS A 2.5 7,8
58 kuntha IE low dose 20 XII HI BO 29.7 9 PRIMI 38 Y 150/110 2 H,↓UO CS FP A 2.4 7,8
59 sumathi IE low dose 27 UE HI UB 18 PRIMI 36 160/110 3 H,V F,D,T LN A 1.6 7,8
60 shanthi IE low dose 24 Gr HI BO 10 PRIMI 37 160/120 2 H,V F,P,I CS CX A 2.5 7,8
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61 bharathy IE low dose 21 V HI UB 24 PRIMI 37 150/110 2 CS CX A 1.5 3,5 hypotonia Y
62 mayuri IE low dose 23 XII HI BO 8 PRIMI 38 Y 170/120 4 F,P,M CS FD A 3.1 7,8
63 asmath IE low dose 21 XII M UB 8 G3P2L2 39 160/110 3 LN A 1.75 4,6 Hypotonia Y
64 nalini IE low dose 22 V HI BO 19 13 PRIMI 34 150/100 2 LN A 2.9 7,8
65 selvi IE low dose 21 V HI BO 20 10 G2A1 37 Y 130/100 3 F,P,T ↓DTR LN A 2.75 7,8
66 jaya IE low dose 22 VIII HI BO 23.8 11 PRIMI 39 Y 160/120 4 F,V,P CS FD A 3.25 7,8
67 usha IE low dose 27 II HI UB 24.5 10 G2P1L1 37 180/110 3 H F,P CS FD A 2.6 7,8
68 vijaylakshmi IE low dose 20 V HI BO 26.7 14 PRIMI 33 160/106 2 F,D,P Y LN A 1.25,1.25 5,6 RD Y
69 farhana IE low dose 25 X M UB 8 PRIMI 34 160/110 3 LN E 1.25 3,5
70 mala IE low dose 24 XII HI BO 22.8 5 PRIMI 40 Y 160/110 3 F,P,I Y LN A 1.25 5,,6 RD,hypotonia Y
71 vanitha IE low dose 22 Gr HI BO 17.9 24 G2P1L0 37 Y 170/120 3 F,P,T CS P.CS A 1.5 6,7 RD Y
72 jaya IE low dose 28 Gr HI BO 27.5 5 G2P1L1 39 Y 180/120 4 H,BV LN A 2.75 7,8
73 chithra IE low dose 22 XII HI BO 7 PRIMI 31 140/106 2 H,BV F,P,I LN SB 2
74 vijaya IE low dose 23 XII HI BO 25.4 5 PRIMI 40 Y 150/110 3 H F,D,T Y LN A 3
75 devi IE low dose 29 X HI BO 24.5 6 G2P1L1 40 160/110 4 H F,T CS FP A 2.7 7,8
76 vijaya IE low dose 25 X HI UB 23.9 10 PRIMI 40 Y 200/130 3 H,V,BV F,P,I CS FD A 2.5 7,8
77 sivagami IE low dose 20 V HI BO 22.6 14 PRIMI 34 170/120 4 F,T LN A 2 6,8 IUGR
78 maheswari IE low dose 20 V HI BO 26.2 6 PRIMI 38 170/110 2 F CS FP A 3.6 7,8
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79 latha IE low dose 20 XII HI BO 29.9 5 G2P1L1 39 150/110 2 F,P,I CS P.CS A 3.4 6,8
80 maheswari AP low dose 30 V HI BO 25.3 15 G2P1L1 34 Y 160/100 3 F,P,I LN SB 1.6
81 sahaya mary AP low dose 23 II HI BO 18.52 9 PRIMI 26 160/110 3 F,D,T LN SB 1.6
82 deivayani AP low dose 20 VIII HI BO 23.5 25 PRIMI 34 130/80 3 CS Abruption A 2.2 ,6,8
83 selvabharathy AP low dose 29 V HI UB 20.9 13 G2P1L1 34 160/110 3 F,P,M CONVULSION LN A 1.9 6,7 Hypotonia Y
84 madhavi AP low dose 26 X HI BO 9 G2P1L1 27 140/90 4 LN SB 0.8
85 asmath AP low dose 21 XII M BO 20 7 G3P2L2 39 150/110 3 F,P,T LN A 2.75 7,8
86 chithra AP low dose 19 XII HI UB 8 PRIMI 38 160/110 3 F,P CS CX A 3.3 7,8
87 selvarani AP low dose 24 V HI BI 23.3 11 G2P1L1 36 130/104 4 H LN A 1.6 6,7
88 mahalakshmi AP low dose 22 Gr HI BO 29.5 8 PRIMI 38 Y 140/130 3 F,V,T LN SB 1.5
89 kowsalya AP low dose 19 XII HI UB 24.8 8 PRIMI 36 140/110 2 H,V,BV VENTILATOR CS DMC A 2..75 7,8
90 nandhini AP low dose 21 V HI BO 25.3 13 PRIMI 31 150/100 3 F,P,T CS FP SB 1.2
91 saraswathy AP low dose 25 XII HI BO 24.4 13 G3P2L2 32 Y 150/110 3 F,P,M,I ↓UO RF LN A 1.6 7,8 IUGR Y
92 malar AP low dose 21 XII HI BO 22.9 8 PRIMI 28 160/100 3 LN A 1.4 6,7 hypotonia Y
93 nirmala AP low dose 25 X HI BO 25.4 17 PRIMI 36 150/100 3 LN SB O.9
94 selvi AP low dose 24 Gr HI BO 23.8 15 PRIMI 32 190/130 3 F,V LN A 2.3 7,8
95 ankaleshwari AP low dose 20 II HI UB 22.5 12 PRIMI 38 170/100 4 F,P,I CS FP E 1.4 3,6 hypotonia,RD Y
96 deedomal AP low dose 22 II HI UB 20.4 10 PRIMI 38 140/110 4 VENTILATOR CS DMC A 2.95 7,8
97 satya AP low dose 23 UE HI UB 12 PRIMI 36 150/110 3 H,↓UO F,P CS FD A 2.2 3,6
98 praveena PP low dose 21 II HI UB 24.2 5 P1L1 Y 150/110 3 Y LN A 2.8 7,8
99 janaki PP low dose 22 II HI UB 26.1 9 P1L1 Y 150/110 4 CS A 3.5 7,8
100 deepa PP low dose 19 XII HI BO 25 5 P1L1 Y 140/110 3 F,P,M CONVULSION LN A 3.2 7,8
Note : IE minent eclampsia BO ked outside E epigastric pain I induration CS arean section
AP epartum eclampsia BI ooked IOG ↓UOeased urine output Ab abscess LN our naturale
PP tpartum eclampsia UB NBOOKED F flushing T thirst DMC maternal condition
HI hindu H eadache D ness/drowsiness A alive FI ed induction
M muslim V vomitting P pain DB dead born FP re to progress
C christian BV ring of vision M uscle weakness RD iratory distress CX ourable cervix
UE uneducated N nausea Y yes DTR p tendon reflex FD tal distress
Gr graduate P para BP blood presurre RF enal failure P.CS evious lscs
G gravida L ive birth A abortion CVT l vein thrombosis PPH um haemorrhage
COLUMN 13/ 21 Y hypertensive given E expired
COLUMN 28 Y NICU admission MRP emoval of placenta
